JP2003530079A - Human transferase molecule - Google Patents

Abstract

  (57) [Summary]   The present invention relates to human transferase molecules (HTFS) and polynucleotides that identify and encode HTFS. The present invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The present invention also provides methods for diagnosing, treating, and preventing a disease associated with HTFS expression.

Description

Detailed Description of the Invention

TECHNICAL FIELD The present invention relates to a nucleic acid sequence and amino acid sequence of human transferase, and also to diagnosis / treatment / prevention of diseases of abnormal cell proliferation and diseases of immune system, and nucleic acid sequences and amino acids of human transferase molecule. It relates to the use of these sequences in assessing the effect of exogenous compounds on the expression of the sequences.

BACKGROUND OF THE INVENTION Transferases are enzymes that catalyze the transfer of molecular groups. The reaction is oxidation,
It is often specific for a particular site on a substrate or certain substrates, with reduction or covalent cleavage. Transferases are involved in the synthesis and degradative functions of cellular components, and in reactions essential for cell regulation. Cellular functions include cell signaling, cell proliferation, inflammation, apoptosis, secretion, and excretion. Transferases are often classified by the type of group to which they are transferred. For example, methyltransferase transfers a one-carbon methyl group, aminotransferase transfers a nitrogenous amino group, and similarly named enzymes include aldehyde groups or ketone groups, as well as small enzyme groups such as coenzyme A, Transfers an acyl group, a glycosyl group, an alkyl or allyl group, an isoprenyl group, a saccharyl group, a phosphorus-containing group, a sulfur-containing group, or a selenium-containing group.

Acyl transferases include peroxisomal carnitine octanoyl transferases involved in the fatty acid beta-oxidation pathway and mitochondrial carnitine palmitoyl transferases involved in fatty acid metabolism and transport.
Choline O-acetyltransferase catalyzes the biosynthesis of the neurotransmitter acetylcholine.

Aminotransferases play important roles in protein synthesis and degradation and also contribute to other processes. For example, the aminotransferase 5-aminolevulinate synthase catalyzes the addition of succinyl CoA to glycine, the first step in heme biosynthesis. Another aminotransferase is
Involved in pathways important for nerve function and metabolism. For example, glutamine phenylpyruvate aminotransferase, also known as glutamine transaminase K (GTK), catalyzes multiple reactions involving pyridoxal phosphate cofactors.
GTK catalyzes the reversible conversion of L-glutamine and phenylpyruvic acid to 2-oxoglutaramate and L-phenylalanine. Other amino acid substrates of GTK include L-methionine, L-histidine, and L-tyrosine. GTK also catalyzes the conversion of kynurenine to kynurenic acid. This kynurenic acid is a tryptophan metabolite, an antagonist of the N-methyl-D-aspartic acid (NMDA) receptor in the brain, and may act as a neuromodulatory function. Altered kynurenine metabolic pathways may be associated with multiple neurological disorders. GTK also plays a role in the metabolism of glutathione-bound halogenated xenobiotics, causing nephrotoxicity in rats and neurotoxicity in humans. GTK is expressed in kidney, liver, and brain. Both human GTK and rat GTK contain a putative pyridoxal phosphate binding site (ExPASy ENZYME: EC 2.6.1.64; P
erry, SJ et al. (1993) Mol. Pharmacol. 43: 660-665, Perry, S. et al. (1995).
FEBS Lett. 360: 277-280, and Alberti Giani, D. et al. (1995) J. Neurochem. 6
4: 1448-1455). The second aminotransferase involved in this pathway is kynurenine / α-aminoadipate aminotransferase (AadAT). AadA
T catalyzes the reversible conversion of α-aminoadipic acid and α-ketoglutarate to α-ketoadipate and L-glutamate during metabolism of lysine. AadAT also
It also catalyzes the transfer of amino groups from kynurenine to kynurenic acid. Cytosolic AadAT is expressed in kidney, liver, and brain (Nakatani, Y. et al. (1970) Biochim. Biophys.
Acta 198: 219-228, Buchli, R. et al. (1995) J. Biol. Chem. 270: 29330-293.
35).

Glycosyltransferases include the mammalian UDP-glucouronosyl transferases, a family of membrane-bound microsomal enzymes. This membrane-bound microsomal enzyme catalyzes the transfer of glucouronic acid to lipophilic substrates in reactions that play an important role in detoxification and excretion of drugs, carcinogens, and other foreign substances. Mammalian UD, another mammalian glycosyltransferase
P-galactose ceramide transferase catalyzes the transfer of galactose to ceramide in the synthesis of galactocerebrosides in the myelin membrane of the nervous system. UDP-glycosyltransferases share a conserved signature domain of about 50 amino acid residues (PROSITE: PDOC00359, http://expasy.hcuge.ch/
sprot / prosite.html).

Methyltransferases are involved in various pharmacologically important processes.
Nicotinamide N-methyltransferase catalyzes the N-methylation of nicotinamide and other pyridines. This is an important step in the intracellular processing of drugs and other foreign compounds. Phenylethanolamine N-methyltransferase catalyzes the conversion of noradrenaline to adrenaline. 6-O-methylguanine-DNA methyltransferase reverses DNA methylation. This is an important step in carcinogenesis. Uroporphyrin which catalyzes the transfer of two methyl groups from S-adenosyl-L-methionine to uroporphyrinogen III-
III C methyltransferase is the first specific enzyme in cobalamin biosynthesis. This cobalamin is a food enzyme with reduced uptake in pernicious anemia. Protein-arginine methyltransferase catalyzes post-translational methylation of arginine residues in proteins, resulting in mono- or dimethylation of arginine at the guanidino group. Substrates include histones, myelin basic proteins, and heterologous nuclear nucleoproteins involved in mRNA processing, splicing, and transport. Protein-arginine methyltransferase plays an important role in methylation in cytokine receptor signaling by interacting with mitogen-upregulated proteins, proteins involved in chronic lymphocytic leukemia, and interferons Possible (Lin, W.-J. et al. (1996) J. Biol. Che
m. 271: 15034-15044; Abramovich, C. et al. (1997) EMBO J. 16: 260-266; and Scott, HS et al. (1998) Genomics 48: 330340).

Phosphotransferases catalyze the transfer of high-energy phosphate groups. Therefore, it is important for reactions requiring energy and energy release reactions. The metabolizing enzyme creatine kinase catalyzes the reversible phosphate transfer between creatine / creatine phosphate and ATP / ADP. Glycocyamine Kinase from ATP to guani
Catalyzes the transfer of phosphate to doacetate, and arginine kinase catalyzes the transfer of phosphate from ATP to arginine. A cysteine-containing active site is conserved in this family (PROSITE: PDOC00103).

Prenyltransferase is a heterodimer composed of α and β subunits that catalyzes the transfer of an isoprenyl group. An example of a prenyl transferase is the mammalian protein farnesyl transferase. The α subunit of farnesyl transferase is composed of five repeats of 34 amino acids each with an invariant tryptophan (PROSITE: PDOC00703).

Saccharyl transferase is a saccharifying enzyme involved in various metabolic processes. For example, oligosacchryl transferase-48 is a receptor for late glycation end products. Accumulation of these end products is observed in the diabetic complications of angiopathy, macroangiopathy, renal failure, and Alzheimer's disease (Thornalley, PJ (1
998) Cell Mol. Biol. (Noisy Le-Grand) 44: 1013-1023).

Coenzyme A (CoA) transferase catalyzes the transfer of CoA between two carboxylic acids. Succinyl CoA: 3-oxoacid CoA transferase
nsferase), for example, transfers CoA from succinyl CoA to a recipient such as acetoacetic acid. Acetoacetic acid is essential for the metabolism of ketone bodies and accumulates in tissues affected by metabolic disorders such as diabetes (PROSITE: PDOC00980).

The discovery of novel human transferase molecules and polynucleotides encoding them is useful in the diagnosis, prevention, and treatment of abnormalities in cell proliferation and diseases of the immune system, and also the nucleic acid sequences and amino acids of human transferase molecules. The need in the art can be met by providing novel compositions useful for the evaluation of foreign compounds that affect the expression of sequences.

(Summary of the Invention) The present invention is collectively referred to as “HTFS”, and individually as “HTFS-1”, “HTFS-2”, and “HTFS-2”.
"HTFS-3", "HTFS-4", "HTFS-5", "HTFS-6", "HTFS-7", "HTFS-8", "HTFS-6"
"HTFS-9", "HTFS-10", "HTFS-11", "HTFS-12", "HTFS-13", "HTFS-14"
, "HTFS-15", "HTFS-16", "HTFS-17", "HTFS-18", "HTFS-19", "H"
TFS-20, HTFS-21, HTFS-22, HTFS-23, HTFS-24, HTFS-25
, "HTFS-26", "HTFS-27", "HTFS-28", "HTFS-29", "HTFS-30", "H"
TFS-31, HTFS-32, HTFS-33, HTFS-34, HTFS-35, HTFS-36
, “HTFS-37”, “HTFS-38”, “HTFS-39”, “HTFS-40”, “HTFS-41”, and “HTFS-42”, which are human transferase purified polypeptides. provide. In one embodiment of the present invention, (a) SEQ ID NO: 1 to 42 (SEQ ID NO: 1-
An amino acid sequence selected from the group consisting of 42), and (b) a natural amino acid sequence having 90% or more sequence identity with the amino acid sequence selected from the group consisting of SEQ ID NO: 1-42; ) A biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (d) an immunogen of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of a sex fragment is provided. Alternatively, an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 1-42 is provided.

Furthermore, the present invention relates to (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42 %
A natural amino acid sequence having the above sequence identity, (c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, (d) SEQ ID NO:
An isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: an immunogenic fragment of the amino acid sequence selected from the group consisting of: 1-42. Alternatively, the polynucleotide is SEQ ID NO: 1-
Encodes a polypeptide selected from the group consisting of 42. Alternatively, the polynucleotide is selected from the group consisting of SEQ ID NO: 43-84.

Further, the present invention provides (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. 90
A natural amino acid sequence having a sequence identity of greater than or equal to%, (c) a biologically active fragment of the amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, (d) SEQ ID
A promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of an immunogenic fragment of the amino acid sequence selected from the group consisting of NO: 1-42 A recombinant polynucleotide comprising is provided. Alternatively, the invention provides a cell transformed with this recombinant polynucleotide. In a further alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The present invention also provides (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. 90
A natural amino acid sequence having a sequence identity of greater than or equal to%, (c) a biologically active fragment of the amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, (d) SEQ ID
Provided is a method for producing a polypeptide containing an amino acid sequence selected from the group consisting of an immunogenic fragment of the amino acid sequence selected from the group consisting of NO: 1-42. This method comprises: (a) culturing cells transformed with a recombinant polynucleotide containing a promoter sequence operably linked to a polynucleotide encoding the polypeptide under conditions suitable for expression of the polypeptide. Steps to do, (b)
Recovering the polypeptide so expressed.

Furthermore, the present invention provides (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. 90
A natural amino acid sequence having a sequence identity of greater than or equal to%, (c) a biologically active fragment of the amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, (d) SEQ ID
There is provided an isolated antibody that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of an immunogenic fragment of the amino acid sequence selected from the group consisting of NO: 1-42. .

Further, the invention provides (a) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84 and (b) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84. A native polynucleotide sequence having 90% or more sequence identity with the sequence,
(C) A polynucleotide sequence complementary to (a) above, (d) a polynucleotide sequence complementary to (b) above, and (e) an RNA equivalent of (a) to (d) above. Provided an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of: Alternatively, the polynucleotide comprises at least 60 contiguous nucleotides.

Further, the present invention provides (a) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84 and (b) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84. A native polynucleotide sequence having 90% or more sequence identity with
c) a polynucleotide sequence complementary to (a) above, (d) a polynucleotide sequence complementary to (b) above, and (e) an RNA equivalent of (a) to (d) above. A method of detecting a target polynucleotide having a polynucleotide sequence comprising a polynucleotide sequence selected from the group of: in a sample. This method
(A) a step of hybridizing the sample with a probe containing at least 20 consecutive nucleotides constituting a sequence complementary to the target polynucleotide in the sample, wherein the probe and the target polynucleotide or a fragment thereof Said probe specifically hybridizes to said target polynucleotide under conditions whereby a hybridization complex is formed with
(B) detecting the presence or absence of the hybridization complex and, if present, optionally measuring the yield. Alternatively, the probe comprises at least 60 contiguous nucleotides.

The present invention further provides (a) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84 and (b) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84. A native polynucleotide sequence having 90% or more sequence identity with
c) a polynucleotide sequence complementary to (a) above, (d) a polynucleotide sequence complementary to (b) above, and (e) an RNA equivalent of (a) to (d) above. A method of detecting a target polynucleotide having a polynucleotide sequence comprising a polynucleotide sequence selected from the group of: in a sample. This method
(A) amplifying the target polynucleotide or a fragment thereof using polymerase chain reaction amplification; and (b) detecting whether the amplified target polynucleotide or a fragment thereof is present and, if present, Optionally measuring the yield.

Furthermore, the present invention relates to (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. %
A natural amino acid sequence having the above sequence identity, (c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, (d) SEQ ID NO:
: 1-42 and an immunogenic fragment of an amino acid sequence selected from the group consisting of: and an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of: and a suitable pharmaceutical excipient. A composition is provided. In one example, a composition is provided that comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. Furthermore, the present invention provides a method for treating a disease associated with decreased expression of functional HTFS or a symptom thereof, which comprises administering the composition to a patient.

Furthermore, the present invention relates to (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. %
A natural amino acid sequence having the above sequence identity, (c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, (d) SEQ ID NO:
A method for screening a compound effective as an agonist of a polypeptide containing an amino acid sequence selected from the group consisting of an immunogenic fragment of the amino acid sequence selected from the group consisting of: 1-42. The method comprises the steps of (a) exposing a sample containing the polypeptide to a compound, and (b) detecting agonist activity of the sample. Alternatively, the invention provides a composition comprising an agonist compound identified by this method and a suitable pharmaceutical excipient. In a further alternative, the invention provides a functional HT comprising the administration of this composition to a patient.
Disclosed is a method for treating a disease associated with decreased expression of FS and a symptom thereof.

Furthermore, the present invention provides (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. 90
A natural amino acid sequence having a sequence identity of greater than or equal to%, (c) a biologically active fragment of the amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, (d) SEQ ID
A method for screening a compound effective as an antagonist of a polypeptide containing an amino acid sequence selected from the group consisting of an immunogenic fragment of the amino acid sequence selected from the group consisting of NO: 1-42 . The method comprises the steps of (a) exposing a sample containing the polypeptide to a compound, and (b) detecting antagonist activity of the sample. Alternatively, the invention provides
There is provided a composition comprising an antagonist compound identified by this method and a suitable pharmaceutical excipient. In a further alternative, the present invention provides a method of treating a disease or condition associated with overexpression of functional HTFS, which method comprises the administration of this composition to a patient.

Furthermore, the present invention relates to (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. %
A natural amino acid sequence having the above sequence identity, (c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, (d) SEQ ID NO:
A method for screening a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of: 1-42 and an immunogenic fragment of the amino acid sequence selected from the group consisting of: 1-42. The method comprises the steps of (a) binding the polypeptide to at least one compound under suitable conditions, and (b) detecting the binding of the polypeptide to the test compound to specifically bind the polypeptide. Identifying a compound that binds to.

Further, the present invention relates to (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42. %
A natural amino acid sequence having the above sequence identity, (c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, (d) SEQ ID NO:
A method for screening a compound that regulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of an immunogenic fragment of the amino acid sequence selected from the group consisting of: 1-42. This screening method comprises the steps of (a) binding the polypeptide to at least one compound under conditions permitting its activity, and b) assessing the activity of this polypeptide in the presence of the test compound. And (c) comparing the activity of this polypeptide in the presence of this test compound with the activity of this polypeptide in the absence of this test compound, in the presence of this test compound. The change in the activity of this polypeptide in γ is characteristic of suggesting the presence of a compound that regulates the activity of this polypeptide.

The invention further provides a method of screening for compounds that are effective in altering the expression of a target polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO: 43-84, comprising (a) Provided is a screening method comprising exposing a sample containing the target polynucleotide to a compound, and (b) detecting a change in the expression of the target polynucleotide.

The present invention further provides a method of assessing the toxicity of a test compound. This method
(A) treating a biological sample containing nucleic acid with the test compound, and (b)
Hybridizing nucleic acid of the treated biological sample with a probe,
(C) measuring the yield of the hybridization complex, and (d) comparing the yield of the hybridization complex in the treated biological sample with the yield of the hybridization complex in the untreated biological sample. And the difference in yield of hybridization complex in the treated biological sample is indicative of toxicity of the test compound. The probe in this method comprises (1) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84 and (2) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84. A native polynucleotide sequence having at least 90% sequence identity, (3
) A polynucleotide sequence complementary to (1) above, (4) a polynucleotide sequence complementary to (2) above, and (5) an RNA equivalent of (1) to (4) above. It comprises at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group. In addition, the hybridization is performed under the condition that a specific hybridization complex is formed between the probe and the target polynucleotide of the biological sample. Further, the target polynucleotide is (1) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84, and (2) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84. A natural polynucleotide sequence having a sequence identity of at least 90% with (3) a polynucleotide sequence complementary to (1) above, (4) above (
A polynucleotide sequence complementary to 2) and (5) the RNA equivalent of (1) to (5) above. Alternatively, the target polynucleotide is a fragment of the polynucleotide sequence.

(Description of the Present Invention) Before describing the protein and nucleic acid sequences and methods of the present invention, the present invention is not limited to the specific devices and materials and methods disclosed herein, and its embodiments are modified. Please understand what you can do. Also, the terminology used herein is for the purpose of describing particular embodiments only and is limited only by the scope of the following claims,
It should also be understood that it is not intended to limit the scope of the invention.

[0028] In the present specification and claims, "a", "the (these), etc."
Note that includes plural forms unless the context clearly indicates otherwise. Thus, for example, “a host cell” includes a plurality of host cells, “antibody” includes a plurality of antibodies, and equivalents well known to those skilled in the art.

All scientific and technical terms used herein, unless defined otherwise,
It has the same meaning as commonly understood by a person skilled in the art to which the present invention belongs.
Although any apparatus and materials and methods similar or equivalent to those described herein can be used in the practice and testing of the present invention, suitable apparatus and materials and methods are described herein.
All references mentioned herein are cited to describe and disclose the cell lines, protocols, reagents, vectors described in the references that may be used in connection with the present invention. The mere fact that the conventional invention is cited does not mean that the novelty of the present invention is impaired.

Definitions The term “HTFS” is obtained substantially from all species including natural, synthetic, semi-synthetic or recombinant (especially mammals including bovine, ovine, porcine, murine, equine and human). Refers to the purified amino acid sequence of HTFS.

The term “agonist” refers to a molecule that enhances or mimics the biological activity of HTFS. This agonist either interacts directly with HTFS or interacts with components of the biological pathways involving HTFS to regulate the activity of HTFS such as proteins, nucleic acids, carbohydrates, small molecules, any other compound or The composition may be included.

The term "allelic variant sequence" refers to another form of the gene encoding HTFS. The allelic variant sequence results from at least one mutation in the nucleic acid sequence resulting in a variant mRNA or variant polypeptide, the structure or function of which may or may not change. Some genes have no natural allelic variants,
There are one or many. Generally, mutations that give rise to allelic variant sequences are due to natural deletions, additions, or substitutions of nucleotides. Each of these mutations, either alone or concurrently with other mutations, occurs one or more times within a given sequence.

A “mutant” nucleic acid sequence that encodes HTFS refers to a polypeptide that has the same polypeptide as HTFS or at least one of the functional properties of HTFS, even though various nucleotide deletions, insertions, or substitutions have occurred. . This definition includes improper or unexpected hybridization of an HTFS-encoding polynucleotide sequence with an allelic variant at a position other than the normal chromosomal locus, as well as specific oligonucleotide probes of the HTFS-encoding polynucleotide. Includes polymorphisms that are easily or difficult to detect using. The encoded protein may also be mutated and may contain deletions, insertions, or substitutions of amino acid residues which result in silent changes and are functionally equivalent to HTFS. Intentional amino acid substitutions are similar in terms of residue polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathicity, as long as the activity of HTFS is retained biologically or immunologically. Can be based on. For example, negatively charged amino acids can include aspartic acid and glutamic acid, and positively charged amino acids can include lysine and arginine. Amino acids with similar hydrophilicity values and having polar uncharged side chains can include asparagine, glutamine, serine, threonine. Amino acids with similar hydrophilicity values and having uncharged side chains can include leucine, isoleucine, valine, glycine, alanine, phenylalanine and tyrosine.

The terms “amino acid” and “amino acid sequence” refer to oligopeptide, peptide, polypeptide, protein sequences, or any fragment thereof, including naturally occurring and synthetic molecules. When "amino acid sequence" refers to the sequence of a naturally occurring protein molecule,
"Amino acid sequence" and like terms are not intended to limit the amino acid sequence to the complete and intact amino acid sequence associated with the protein molecule described.

The term “amplification” refers to making copies of nucleic acid sequences. Amplification is generally performed by the polymerase chain reaction (PCR) technique well known in the art.

The term “antagonist” is a molecule that inhibits or attenuates the biological activity of HTFS. Antagonists are antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition that directly interacts with HTFS or interacts with components of the biological pathways in which HTFS is involved to regulate HTFS activity. May include proteins such as things.

The term “antibody” refers to intact molecules such as Fab and F (ab ′) ₂ capable of binding antigenic determinants and fragments thereof, Fv fragments. Antibodies that bind HTFS polypeptides can be produced using intact molecules, or fragments thereof, containing small peptides that immunize the antibody.
The polypeptide or oligopeptide used to immunize an animal (eg, mouse, rat, or rabbit) can be synthesized from the translation of RNA or chemically and is optionally conjugated with a carrier protein. It is also possible. Commonly used carriers that are chemically linked to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemonean (KLH). The conjugated peptide is then used to immunize the animal.

The term “antigenic determinant” refers to the region (ie, epitope) of a molecule that makes contact with a particular antibody.
Refers to. When a protein or a fragment of a protein is used to immunize a host animal, various regions of this protein are antibodies that specifically bind to an antigenic determinant (a specific region on the protein or a three-dimensional structure). Can induce the production of The antigenic determinant may compete with the intact antigen (ie, the immunogen used to elicit an immune response) to bind the antibody.

As used herein, "antisense" refers to any composition capable of base pairing with the sense (coding) strand of a particular nucleic acid sequence. DNA in the antisense component
, RNA, peptide nucleic acid (PNA), and modified backbone such as phosphorothionate, methylphosphonate, and benzylphosphonate
e.g., an oligonucleotide having an e linkage), an oligonucleotide having a modified sugar such as 2'-methoxyethyl sugar or 2'-methoxyethoxy sugar, and 5-methylcytosine or 2'-deoxyuracil, 7-deaza-2 ' -Oxynucleotides with modified bases such as deoxyguanosine may be included. Antisense molecules can be produced by any method, including chemical synthesis and transcription. Once introduced into a cell, the complementary antisense molecule base pairs with the natural nucleic acid sequence produced by the cell to form a duplex and inhibit transcription or translation. The expression "negative" or "minus" is the antisense strand, and the expression "positive" or "plus" is the sense strand.

The term “biologically active” refers to a protein that has the structural, regulatory, or biochemical function of a natural molecule. Similarly, the term "immunologically active" or "immunogenic" refers to the fact that natural or recombinant HTFS, synthetic HTFS or any oligopeptide thereof, is directed to the specific immune response of a suitable animal or cell. Refers to the ability to induce and bind to a particular antibody.

The term “complementary” refers to the relationship between two single-stranded nucleic acid sequences that anneal by base pairing. For example, the sequence "5'AGT3 '" is paired with the complementary sequence "3'TCA5'".

“Composition comprising a given polynucleotide sequence” or “composition comprising a given amino acid sequence” refers broadly to any composition comprising a given nucleotide or amino acid sequence. The composition may include a dry formulation or an aqueous solution.
A composition comprising a polynucleotide sequence encoding HTFS or a fragment of HTFS can be used as a hybridization probe. This probe can be stored in a freeze-dried state and can be bound to a stabilizer such as sugar. In hybridization, the probe is developed in an aqueous solution containing salts (eg, NaCl) and detergents (eg, SDS: sodium dodecyl sulfate) and other substances (eg, Denhardt's solution, dried milk, salmon sperm DNA, etc.). obtain.

The “consensus sequence” is obtained by repeatedly analyzing the DNA sequence in order to separate unnecessary bases, and 5 ′ and / or 5'and / or using the XL-PCR kit (PE Biosystems, Foster City CA).
Or nucleic acid sequence extended in the 3'direction and re-sequenced, or GEL
VIEW Fragment Construction System (GCG, Madison, WI) or Phrap (University of Wash
(ington, Seattle WA), etc., and refers to nucleic acid sequences constructed from one or more overlapping cDNAs or ESTs or genomic DNA fragments using a computer program for fragment construction. Some consensus sequences are constructed by both extension and overlap.

The term “conservative amino acid substitution” refers to a substitution that does not significantly alter the properties of the original protein. That is, the substitution does not significantly change the structure or function of the protein,
The structure of the protein, in particular its function, is preserved. The following shows conservative amino acid substitutions in which the original amino acid of one protein is replaced with another amino acid. Original residue Conservative substitution Ala Gly, Set Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln , Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile . Leu, Thr In general, in the case of conservative amino acid substitutions, a) the backbone structure of the polypeptide in the substituted region, eg β-sheet or α-helix conformation, b) the charge of the molecule at the substituted site or Hydrophobic and / or c) most of the side chains are retained.

The term “deletion” refers to a change in an amino acid sequence that lacks one or more amino acid residues, or a change in a nucleic acid sequence that lacks one or more nucleotides.

The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of polynucleotide sequences include, for example, replacement of hydrogen with an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide has at least one biological or immunological function of a natural molecule (unmodified molecule).
Encodes a polypeptide that maintains one. Derivative polypeptide is a polypeptide modified by glycosylation, polyethylene glycolation, or any similar process that maintains at least one of the biological or immunological functions of the original polypeptide. That is.

“Detectable label” refers to a reporter molecule or enzyme that is capable of producing a measurable signal, either covalently or non-covalently attached to a polynucleotide or polypeptide.

The term “fragment” refers to a unique portion of HTFS or a polynucleotide encoding HTFS that is identical to its parent sequence but shorter than that sequence. The maximum length of a "fragment" is the parent sequence minus one nucleotide / amino acid residue. For example, a fragment contains 5 to 1000 consecutive nucleotides or amino acid residues. Probe, primer, antigen,
The therapeutic molecule, or fragment used for other purposes, comprises at least 5, 10, 15,
It is the length of 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or 500 consecutive nucleotides or amino acid residues. Fragments may also be preferentially selected from particular regions of the molecule. For example, a polypeptide fragment may comprise a predetermined length of contiguous amino acids selected from the first 250 or 500 amino acids shown in the given sequence (or the first 25% or 50% of the polypeptide). . These lengths are examples, and any length described in the specification including the sequence listing and the tables and drawings can be included in the embodiments of the present invention.

A fragment of SEQ ID NO: 43-84 is, for example, a region of unique polynucleotide sequence that uniquely identifies SEQ ID NO: 43-84, which differs from other sequences in the genome from which this fragment was obtained. including. Certain fragments of SEQ ID NO: 43-84 are useful, for example, in hybridization and amplification techniques, or similar methods of distinguishing SEQ ID NO: 43-84 from related polynucleotide sequences. The exact fragment length and region of SEQ ID NO: 43-84 that matches a fragment can be routinely determined by techniques common in the art based on the purpose of the fragment.

Certain fragments of SEQ ID NO: 1-42 are encoded by certain fragments of SEQ ID NO: 43-84. Certain fragments of SEQ ID NO: 1-42 contain regions of unique amino acid sequence that uniquely identify SEQ ID NO: 1-42. For example, one fragment of SEQ ID NO: 1-42 is specifically SE
It is useful as an immunogenic peptide for the production of antibodies that recognize Q ID NO: 1-42. The exact fragment length and region of SEQ ID NO: 1-42 that matches a given fragment can be routinely determined by techniques common in the art based on the purpose of the fragment.

A “full length” polynucleotide sequence is a sequence that has at least one translation initiation codon (eg, methionine), followed by an open reading frame and a translation stop codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

“Homology” is sequence similarity between two or more polynucleotide sequences or between two or more polypeptide sequences. This sequence similarity can be translated into sequence identity.

The term “percent identity” or “% identity” with respect to a polynucleotide sequence refers to matching residues between two or more polynucleotide sequences that are aligned using a standardized algorithm. It is a percentage. Such algorithms can insert gaps in the sequences to make a more meaningful comparison between the two sequences in a standardized and reproducible manner to optimize the alignment between the two sequences.

The percent identity between polynucleotide sequences can be determined using the default parameters of the CLUSTAL V algorithm incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package and includes a suite of molecular biology analysis programs (DNASTAR, Madison W
I). This CLUSTAL V is for Higgins, DG and PM Sharp (1989) CABIOS
5: 151-153, Higgins, DG et al. (1992) CABIOS 8: 189-191. For pairwise alignments of polynucleotide sequences, the default parameter is Kt.
Set uple = 2, gap penalty = 5, window = 4, and “diagonals saved” = 4. A "weighted" residue weight table was selected as the default. The percent identity is reported by CLUSTAL V as the "percentage similarity" between the aligned polynucleotide sequences.

Alternatively, a set of commonly used and freely available sequence comparison algorithms is
NCBI, Bethesda, MD, and Internet (http://WWW.ncbi.nlm.nih.gov/BLAS
National Center for Biotechnology Information (NCB)
I) Basic Local Alignment Search Tool (BLAST) (Altschul, SF et al. (1990) J
Mol. Biol. 215: 403-410). This suite of BLAST software includes a variety of sequence analysis programs, including "blastn" used to align known polynucleotide sequences with other polynucleotide sequences in various databases. A tool called "BLAST 2 Sequences" is available,
Used to directly compare pairs of two nucleotide sequences. "BLAST 2 Sequen
"ces" can be used interactively by accessing http://WWW.ncbi.nlm.nih.gov/gorf/b12.html. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (described below). The BLAST program is commonly used with gaps and other parameters that set defaults. For example,
When comparing two nucleotide sequences, one may blast with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set to default parameters.
will use n. Such default parameters are, for example, the following: Like Filter: on.

Percentage identity may be measured, for example, for the entire length of a given sequence, as determined by a particular SEQ ID NO, or for shorter lengths, for example at some large given Fragments obtained from the sequence, eg at least 20 or 30 consecutive
, 40, 50, 70, 100, 200 nucleotide fragments. Such lengths are merely exemplary, and fragments of any length of the sequences set forth in the specification including sequence listing and tables and figures may be used to indicate the length at which percent identity is measured. it can.

Nucleic acid sequences that do not show high identity may still code for similar amino acid sequences due to the degeneracy of the genetic code. It is to be understood that degeneracy can be utilized to alter nucleic acid sequences to produce different nucleic acid sequences each encoding substantially the same protein.

The term “percent identity” or “% identity” as used in polypeptide sequences refers to matching residues between two or more polypeptide sequences that are aligned using a standardized algorithm. It is a percentage. Methods of polypeptide sequence alignment are well known. Some alignment methods consider conservative amino acid substitutions. Such conservative substitutions, described in detail above, generally conserve charge and hydrophobicity at the site of substitution, and result in polypeptide structure (and thus function) as well.
Is saved.

The percent identity between polypeptide sequences can be determined using the default parameters of the CLUSTAL V algorithm incorporated into the MEGALIGN version 3.12e sequence alignment program (supra). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are Ktuple = 1, gap
Set penalty = 3, window = 5, and “diagonals saved” = 5. The PAM250 matrix is selected as the default residue weight table. Similar to polynucleotide alignments, the percent identity of paired aligned polypeptide sequences is reported by CLUSTAL V as the "percentage of similarity."

Alternatively, the NCBI BLAST software suite is used. For example, when making a pairwise comparison of two polypeptide sequences, one would use blastp with the "BLAST 2 Sequences" tool Version 2.0.12 (Apr-21-2000) set with default parameters. . Such default parameters are, for example, Matrix: BLOSUM62 Open Gap: 11 and Extension Gap: 1 penalties Gap x drop-off: 50 Expect: 10 Word Size: 3 Filter: on.

Percent identity may be measured, for example, for the entire length of a given polypeptide sequence, as determined by a particular SEQ ID NO, or for shorter lengths, eg, some large Fragments obtained from a given polypeptide sequence may be measured, for example, for the length of fragments of at least 15, 20, or 30, 40, 50, 70, 150 contiguous residues. Such lengths are merely exemplary, and fragments of any length of the sequences set forth in the specification including sequence listing and tables and figures may be used to indicate the length at which percent identity is measured. it can.

“Human Artificial Chromosome (HAC)” is a DNA of about 6 kb (kilobase) to 10 Mb in size.
A linear minichromosome containing all the elements necessary for the segregation and maintenance of a stable mitotic chromosome, which may include sequences.

The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence of the non-antigen binding region has been altered in order to resemble a more human antibody while retaining its original binding ability.

“Hybridization” refers to the following hybridization conditions.
A single-stranded polynucleotide is the process of annealing to form base pairs with a complementary single strand. Specific hybridization means that two nucleic acid sequences have high homology. Under conditions that permit annealing, specific hybridization complexes are formed and remain hybridized after the washing process. The washing process is particularly important in determining the stringency or stringency of the hybridization process, and under more stringent conditions, non-specific binding, ie binding of pairs of nucleic acid strands that are not perfectly matched. Is reduced. The conditions under which annealing between nucleic acid sequences is permissible are routinely determined by those of skill in the art and are constant during hybridization, but the washing process involves changing the conditions during which to achieve the desired stringency. Is possible and hybridization specificity is obtained. Annealing conditions are, for example, a temperature of 68 ° C., about 6 × SSC, about 1% (w / v) SDS, and about 100 μg.
/ Ml of sheared and denatured salmon sperm DNA.

In general, hybridization stringency also depends on the temperature at which the washing process is performed. The wash temperature is usually selected to be about 5-20 ° C below the thermal melting point (Tm) of the particular sequence at a given ionic strength and pH. This Tm is
It is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. The formula for calculating the Tm and the conditions for nucleic acid hybridization are well known, Sambrook, J. et al., 1989, Molecular Cloning : A Laboratory Manual , Volume 2 1-3, Cold Spring Harbor Press, Plainvi.
ew NY; Especially described in Chapter 2 of Volume 2.

High stringency hybridization between polynucleotides of the present invention involves a wash step at about 68 ° C. for 1 hour in the presence of about 0.2 × SSC and about 1% SDS. Alternatively, it is carried out at temperatures of 65 ° C, 60 ° C, 55 ° C, 42 ° C. SSC concentrations range from about 0.1 to 2x SSC in the presence of about 0.1% SDS. Blocking reagents are usually used to prevent non-specific hybridization. Such blocking reagents include, for example, about 100 to 200 μg / ml of cleaved and denatured salmon sperm DNA. Organic solvents such as formamide at a concentration of about 35-50% v / v can be used in certain cases such as, for example, RNA-DNA hybridizations. Useful modifications of these wash conditions are well known to those of skill in the art. Hybridization, particularly under highly stringent conditions, may suggest evolutionary similarities between the nucleotides. Such similarities strongly suggest that the nucleotides and encoded polypeptides play a similar role.

The term “hybridization complex” refers to a complex of two nucleic acid sequences formed by hydrogen bonds between complementary bases. Hybridization complexes may be formed in solution (eg, C ₀ t or R ₀ t analysis), or one nucleic acid sequence in solution and a solid support (eg, paper, membrane, filter, chip, pin). ,
Or a slide glass, or any suitable substrate for immobilizing cells and their nucleic acids)
Can be formed with another nucleic acid sequence fixed to.

The term “insertion” or “addition” refers to a change in an amino acid sequence or nucleic acid sequence in which one or more amino acid residues or nucleotides are added, respectively.

“Immune response” refers to a condition associated with inflammatory diseases and trauma, immune disorders, infectious diseases, genetic diseases and the like. These conditions are characterized by the expression of various factors such as cytokines and chemokines, other signaling molecules that affect the cell and systemic defense systems.

The term “microarray” refers to the composition of multiple polynucleotides, polypeptides or other compounds on a substrate.

The term “element” or “array element” refers to a polynucleotide, polypeptide or other compound that has a uniquely designated position on a microarray.

The term “modulation” refers to a change in the activity of HTFS. For example, modulation results in a change in the protein activity or binding properties of HTFS or other biological, functional or immunological properties.

The terms “nucleic acid” and “nucleic acid sequence” refer to nucleotides, oligonucleotides, polynucleotides, or fragments thereof, of single-stranded or double-stranded, sense or antisense strand, genomic origin. Or DNA or RNA of synthetic origin
, Peptide nucleic acid (PNA), any DNA-like substance, and RNA-like substance.

“Operably linked” refers to the condition in which a first nucleic acid sequence and a second nucleic acid sequence are in a functional relationship. For example, a promoter is operably linked to a coding sequence if it affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are very contiguous or contiguous if the regions encoding the two proteins must be joined in the same reading frame.

“Peptide nucleic acid (PNA)” refers to an antisense molecule or anti-gene agent that comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. This terminal lysine renders the composition soluble. PNAs can bind preferentially to complementary single-stranded DNA or RNA to stop elongation of transcripts and polyethylene glycol to prolong life in cells.

“Post-translational modifications” of HTFS include lipidation, glycosylation, phosphorylation, acetylation,
Racemization, proteolytic cleavage and other modifications known in the art can be included. These processes can occur synthetically or biochemically. Biochemical modifications depend on the enzymatic environment of HTFS and may vary by cell type.

The “probe” is a nucleic acid sequence encoding HTFS, a complementary sequence thereof, or a fragment thereof, which is used for detecting the same or allelic nucleic acid sequence, or a related nucleic acid sequence. A probe is an oligonucleotide or polynucleotide that has been isolated with a detectable label or reporter molecule attached. Typical labels include radioisotopes and ligands, chemiluminescent reagents, enzymes. A "primer" is capable of forming complementary base pairs and annealing to a target polynucleotide,
A short nucleic acid, usually a DNA oligonucleotide. After the primer anneals to the polynucleotide, it is extended along the target DNA single strand by a DNA polymerase enzyme. The primer set can be used, for example, for amplification (and identification) of a nucleic acid sequence in a PCR method.

The probes and primers used in the present invention include at least 15 of known sequences.
Of contiguous nucleotides. Longer probes and primers can be used to increase specificity. For example, at least 20 or 25, 30, 30, 40, 50, 60, 70, 80, 90, 100 contiguous of the disclosed nucleic acid sequences.
, 150 nucleotides. It should be understood that probes and primers that are considerably longer than the above examples can be used, and nucleotides of any length shown in the tables and drawings of the present specification and the sequence listing can also be used.

For the preparation and use of the probe and the primer, see, for example, Sambrook,
J. et al., 1989, Name "Molecular Cloning: A Laboratory Manual", 2nd
Editions 1-3 (Cold Spring Harbor Press, Plainview NY), or Ausubel, FM
In 1987, the name "Current Protocols in Molecular Biology" (Greene
Pubi. Assoc. & Wiley-Intersciences, New York NY), and Innis et al.,
In 1990, the name `` PCR Protocols, A Guide to Methods and Applications '' (Acade
mic Press, San Diego CA.). The set of primers for PCR is, for example, Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research
, Cambridge MA), and the like, and can be derived from one known sequence using a computer program for such purpose.

Oligonucleotides used as primers are selected by computer programs well known in the art for primer selection. For example, OLIGO 4.06 software selects primer pairs for PCR, each up to 100 nucleotides,
And is useful for the analysis of large polynucleotides and oligonucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32,000 bases. Similar primer selection programs include additional features that expand capacity. For example, the PrimOU primer selection program (Genome Center at Uni
versity of Texas South West Medical Center, available from Dallas TX)
Since a specific primer can be selected from the megabase sequence, it is useful for designing a primer in a genome-wide scope. Primer3 primer selection program (Whitehead Institute / MIT Center for Genome Research,
(Available from Cambridge MA1) allows users to specify sequences that they want to avoid as primer binding sites.
) ”Can be entered. Primer3 is also particularly useful for the selection of oligonucleotides for microarrays (the source code of the latter two primer selection programs can be obtained from each source and modified to meet the needs of users). Can also). PrimerGen Program (UK Human Genome Mapping Pro
(available from the ject Resource Center, Cambridge UK), which designs primers based on multiple sequence alignments, so that they will hybridize to either the most conserved or the least conserved regions of the aligned nucleic acid sequences. Can be selected. Therefore, this program is useful for identifying unique and conserved oligonucleotide or polynucleotide fragments. The oligonucleotide or polynucleotide fragment identified by any of the selection methods described above is, for example, a PCR method, a sequencing primer, a microarray element, or a specific identifying a polynucleotide that is completely or partially complementary to a sample nucleic acid. It is useful for the hybridization technique such as the probe.
The method for selecting the oligonucleotide is not limited to the above method.

As used herein, “recombinant nucleic acid” is a sequence that is not a naturally occurring sequence, but is an artificial combination of two or more distant segments of a sequence. Often, this artificial combination is made by chemical synthesis, but it is more common to engineer remote segments of nucleic acid using genetic engineering techniques such as those described in Sambrook, supra. is there. This "recombinant nucleic acid" also includes a nucleic acid modified by simply adding or substituting a part of the nucleic acid. The recombinant nucleic acid may also include a nucleic acid sequence operably linked to a promoter sequence. Such recombinant nucleic acid can be, for example, part of a vector used to transform a cell.

Alternatively, such a recombinant nucleic acid is a vaccinia virus-based virus that, when used to vaccinate a mammal expressing the recombinant nucleic acid, elicits a defensive immune response in the mammal. It can be part of the vector.

A “regulatory element” is a nucleic acid sequence usually derived from the untranslated region of a gene, including enhancers, promoters, introns and 5 ′ and 3 ′ untranslated regions (UTRs).
)including. Regulatory elements interact with host or viral proteins that regulate transcription, translation, or RNA stability.

A “reporter molecule” is a chemical or biochemical moiety used to label nucleic acids, amino acids or antibodies. Reporter molecules include radionuclides, enzymes, fluorescent agents, chemiluminescent agents, chromophores, substrates, cofactors, inhibitors, magnetic particles and other components known in the art.

In the present specification, the “RNA equivalent” to a DNA sequence is composed of the same linear nucleic acid sequence as the reference DNA sequence, except that the nitrogenous base thymine is replaced with uracil to form a sugar chain. Its spine consists of ribose rather than deoxyribose.

The term “sample” is used in its broadest sense. Samples suspected of containing HTFS-encoding nucleic acid or fragments thereof, or HTFS itself include body fluids, extracts from cells, chromosomes or subcellular organelles isolated from cells, membranes, cells, and solutions. Genomic DNA, RNA, cDNA present in or immobilized on a substrate, tissues or tissue prints and the like may also be included.

The terms “specific binding” and “specifically bind” refer to the interaction between a protein or peptide and an agonist, antibody, antagonist, small molecule, or any natural or synthetic binding composition. Point to. This interaction depends on the presence of a particular structure of the protein recognized by the binding molecule, eg, an antigenic determinant or epitope. For example, when the antibody is specific to the epitope "A", the reaction solution containing the unbound labeled "A" and the antibody is bound to the polypeptide containing the epitope A or the unbound unlabeled "A". Is present, the amount of labeled A bound to the antibody is reduced.

The term “substantially purified” refers to a nucleic acid sequence or amino acid sequence that has been removed from its natural environment and then isolated or separated, such that at least about 60 naturally bound compositions are present. % Removed, preferably about 75% or more removed,
Most preferably, 90% or more is removed.

“Substitution” is the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides.

The term “substrate” refers to any suitable solid or semi-solid support, including membranes and filters, chips, slides, wafers, fibers, magnetic or non-magnetic beads, gels, tubes, plates, polymers, microspheres. Includes particles and capillaries. The substrate has various surface morphologies such as walls or trenches, pins, channels, pores, to which polynucleotides and polypeptides bind.

“Transcriptional image” refers to the pattern of collective gene expression by a particular cell type or tissue under given conditions at a given time.

“Transformation” is the process by which exogenous DNA is introduced into recipient cells.
Transformation can occur under natural or artificial conditions by a variety of methods well known in the art, and can be performed by any well known method of inserting a foreign nucleic acid sequence into a prokaryotic or eukaryotic host cell. You can The method of transformation is selected according to the type of host cell to be transformed. This method includes, but is not limited to, bacteriophage or virus infection, electroporation (electroporation), lipofection, and particulate irradiation. "Transformed" cells include stably transformed cells in which the introduced DNA is capable of replicating autonomously, either as a plasmid or as part of a host chromosome. Further, a cell that transiently expresses the introduced DNA or the introduced RNA within a limited time is also included.

As used herein, the term “genetically modified organism” refers to any organism in which a human has introduced a heterologous nucleic acid into one or more cells of the organism using, for example, gene recombination techniques well known in the art. Yes, and includes, but is not limited to animals and plants. By careful genetic manipulation such as microinjection or infection with recombinant virus, the heterologous nucleic acid is introduced into the cell directly or indirectly into the precursor of the cell. “Genetic manipulation” refers to the introduction of recombinant DNA molecules, rather than the typical cross breeding or in vitro fertilization. Genetically modified organisms according to the invention include bacteria and cyanobacteria, fungi, plants, animals. The isolated DNA of the present invention can be introduced into a host by methods well known in the art, such as infection, transfection, transformation, transconjugation and the like. Techniques for introducing the DNA of the present invention into such organisms are well known and described in Sambrook et al. (1989) supra.

A “variant sequence” of a particular nucleic acid sequence refers to the default parameter setting “BLAST
2 Sequences "tool Version 2.0.9 (May-07-1999) shows that at least 40% identity of a particular nucleic acid sequence to a certain length of that nucleic acid sequence is identified.
The nucleic acid sequence determined to be. Such nucleic acid pairs may, for example, be at least 50% or 60%, 70%, 80%, 85%, 90%, over a length.
It may exhibit 95%, 98%, or more identity. A variant sequence can be represented, for example, as an "allelic" variant sequence (described above) or a "splice" variant sequence, a "species" variant sequence, a "polymorphism" variant sequence. Splice variant sequences may have very high identities to the reference molecule, but alternative splicing of exons during mRNA processing may result in more or less polynucleotides. The corresponding polypeptide may have additional functional domains present in the reference molecule or may lack domains present in the reference molecule. Species variant sequences are polynucleotide sequences that vary from species to species. The resulting polypeptides have a high degree of amino acid identity with each other. Polymorphic variant sequences differ in the polynucleotide sequence of a given gene from a given species and the species. The polymorphic variant sequence also includes one of the polynucleotide sequences
A "single nucleotide polymorphism" (SNP) that differs by two nucleotides may also be included. The presence of SNPs may suggest, for example, a population, a pathological condition, a propensity for a pathological condition.

A “variant” of a particular polypeptide sequence refers to the default parameter setting “
BLAST 2 Sequences "Version 2.0.9 (May-07-1999) blastp has determined that the identity of a particular polypeptide sequence to a length of a nucleic acid sequence is at least 40%. That is. Such polypeptide pairs may, for example, be at least 50% or 60%, 7
It may exhibit 0%, 80%, 85%, 90%, 95%, 98%, or more identity.

(Invention) The present invention is based on the discovery of a novel human transferase molecule (HTFS) and a polynucleotide encoding HTFS.
It relates to the use of these compositions in therapy and prophylaxis.

Table 1 shows the Incyte clones used to construct the full length nucleotide sequence encoding HTFS. Columns 1 and 2 show the SEQ ID NOs for the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone ID of the Incyte clone in which the nucleic acid encoding each HTFS was identified, and column 4 shows the cDNA library in which those clones were isolated. Row 5: Incyte clones and their corresponding
A cDNA library is shown. The Incyte clones for which the cDNA library is not shown are derived from the pooled cDNA library. In some cases, GenBank sequence identifiers are shown in column 5. Insight clones and GenBs shown in column 5
The ank cDNA sequence is used to construct the consensus nucleotide sequence for each HTFS and is useful as a fragment in hybridization techniques.

Each column of Table 2 shows various properties of each polypeptide of the invention. Column 1 is the SEQ ID NO, column 2 is the number of amino acid residues in each polypeptide, column 3 is the potential phosphorylation site, column 4 is the potential glycosylation site, and column 5 is the signature (sign).
ature) amino acid residues with sequences and motifs, column 6 is related citations and B
Shown are the homologous sequences identified by LAST analysis, and the corresponding citations. In addition, reference is made to a part of this specification. Column 7 shows the method of analysis and possibly the searchable database to which the method of analysis can be applied. The analysis method in column 7 was used to characterize each polypeptide by sequence homology and protein motifs.

The columns of Table 3 show the tissue specificity and diseases, disorders, symptoms associated with the nucleotide sequences encoding HTFS. Column 1 of Table 3 shows the nucleotide sequence numbers (SEQ
ID NO) is shown. These nucleotide fragments are described, for example, in SEQ ID NO: 43-84.
To identify and distinguish SEQ ID NO: 43-84 from related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 2 shows the name of the tissue expressing HTFS and its proportion in all tissues expressing HTFS. Column 3 is a disease or disorder associated with tissues expressing HTFS, symptoms,
And their proportion in all tissues expressing HTFS. Column 4 shows the vector used for subcloning each cDNA library.

Each column of Table 4 is a description of the tissue used to create the cDNA library in which the clone of the cDNA encoding HTFS was isolated. Column 1 is the SEQ ID of the nucleotide
No, column 2 shows the cDNA library from which those clones were isolated, column 3
Shows the origin and details of the tissue corresponding to the cDNA library in column 2.

SEQ ID NO: 44 maps to Chromosome 1 in the 170.1-186.4 centimorgan range. SEQ ID NO: 46 maps to chromosome 11 in the 58.2-59.5 centimorgan range. SEQ ID NO: 48 maps to chromosome 11 in the 67.4-70.9 centimorgan range. SEQ ID NO: 49 maps to chromosome 21 from the 51.6 centimorgan to short arm (p) end range. SEQ ID NO: 52 is 63.3-7 of chromosome 3
Mapped to the 7.4 cmorgan range. SEQ ID NO: 59 is 50 on chromosome 20.
It maps to the 2-53.6 centimorgan range and to the 113.3-118.9 centimorgan range of chromosome 12. SEQ ID NO: 60 is from 62.7 of chromosome 12
Mapped to the 70.6 centimorgan range. SEQ ID NO: 62 is on chromosome 11
Mapped to the 62.5-70.9 centimorgan range. SEQ ID NO: 68 maps to chromosome 11 in the 70.9-72.1 centimorgan range. SEQ ID NO: 78 has been mapped to the 94.4-97.4 centimorgan range of chromosome 23 and the
Mapped to the end range of 2.5 centimorgans to the short arm (p). SEQ ID NO: 85 maps to Chromosome 5 in the 5.5-21.5 centimorgan range, Chromosome 17 to the 53.9-62.9 centimorgan range, and Chromosome 12 in the 84.7-92.5 centmorgan range.
Maps to the centimorgan range. SEQ ID NO: 86 is from chromosome 42.0
It maps to the 45.4 centimorgan range, maps to the 58.2 to 59.5 centimorgan range on chromosome 11, and maps to the 88.1 to 92.6 centimorgan range on chromosome 16.

The present invention also includes variants of HTFS. Preferred variants of HTFS have at least one of the functional or structural characteristics of HTFS and have at least about 80% amino acid sequence identity to the HTFS amino acid sequence, or at least about 90% amino acid sequence. There is identity, and even at least about 95% amino acid sequence identity.

The present invention also provides a polynucleotide encoding HTFS. In a particular embodiment, the invention provides a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO: 43-84 encoding HTFS. SEQ ID NO: shown in the sequence listing
In the polynucleotide sequence of 43-84, the nitrogen base thymine is replaced with uracil,
The backbone of the sugar chain contains an equivalent RNA sequence consisting of ribose rather than deoxyribose.

The present invention also includes mutant sequences of the polynucleotide sequence encoding HTFS. In particular, such variant sequences of the polynucleotide sequence have at least 70% polynucleotide sequence identity with the polynucleotide sequence encoding HTFS, or at least 85% polynucleotide sequence identity, and even at least 95%. Has polynucleotide sequence identity. A particular embodiment of the invention is SEQ ID NO: 43
SEQ ID NO: having at least 70% polynucleotide sequence identity, or at least 85% polynucleotide sequence identity, and even at least 95% polynucleotide sequence identity with a nucleic acid sequence selected from the group consisting of -84. Provided are mutant sequences of a polynucleotide sequence comprising a sequence selected from the group consisting of 43-84. Each of the polynucleotide variants described above encodes an amino acid sequence having at least one functional or structural characteristic of HTFS.

Various polynucleotide sequences encoding HTFS that may be produced by the degeneracy of the genetic code include those that have minimal similarity to polynucleotide sequences of any known naturally occurring gene. Those of ordinary skill in the art will understand. Thus, the present invention may include all of the possible polynucleotide sequence variations that may be created by the selection of combinations based on possible codon choices. These combinations are made on the basis of the standard triplet genetic code applied to the native HTFS polynucleotide sequences, and are considered to be the clear disclosure of all mutations.

Nucleotide sequences that encode HTFS and variants thereof are generally hybridizable under suitable selected stringent conditions to the nucleotide sequences of native HTFS, such as by including unnatural codons. It may be advantageous to generate nucleotide sequences encoding HTFS or its derivatives with substantially different usage codons. Codons can be selected based on the frequency with which a particular codon is utilized by the host to increase the rate at which peptide expression occurs in a particular eukaryotic or prokaryotic host. Another reason for substantially altering the nucleotide sequence encoding HTFS and its derivatives without changing the encoded amino acid sequence is that RNA transcription with favorable properties, such as longer half-life, than transcripts made from the native sequence. It is about making things.

The invention also includes the production of DNA sequences encoding HTFS and its derivatives or fragments thereof, entirely by synthetic chemistry. After construction, the synthetic sequence can be inserted into any of the various available expression vectors and cell lines using reagents well known in the art. In addition, synthetic chemistry can be used to introduce mutations into the sequence encoding HTFS or any fragment thereof.

The present invention further provides a polynucleotide sequence capable of hybridizing to the claimed polynucleotide sequences, particularly SEQ ID NO: 43-84 and fragments thereof, under a variety of stringent conditions. Included (eg Wahl, GM and SL Berger
(1987) Methods Enzymol. 152: 399-407; and Kimmel. AR (1987) Methods En
zymol. 152: 507-511.). Hybridization conditions, including annealing and wash conditions, are described in the "Definitions".

Any of the embodiments of the present invention can be practiced using DNA sequencing methods well known in the art. This method includes, for example, the Klenow fragment of DNA polymerase I, SE
QUENASE (US Biochemical, Cleveland OH), Taq polymerase (PE Biosystems,
Foster City CA), thermostable T7 polymerase (Amersham, Pharmacia Biotech P
iscataway NJ) or ELONGASE amplification system (Life Technologies, Gaithersbu
Enzymes such as a combination of proofreading exonuclease and polymerase as found in rg MD) are used. Preferably, the MICROLAB 2200 liquid transfer system (Hamilt
on, Reno, NV), PTC200 Thermal Cycler200 (MJ Research, Watertown MA) and ABI CATALYST 800 (PE Biosystems). Next, ABI 373 or 377 DNA sequencing system (PE Biosystems)
, MEGABACE 1000 DNA Sequencing System (Molecular Dynamics. Sunnyval
e CA) or other methods well known in the art for sequencing. The resulting sequences are analyzed using various algorithms well known in the art (e.g., Ausubel
, FM (1997) Short Protocols in Molecular Biology , John Wiley & Sons, N
See Meyers, RA (1995) Molecular Biology and Biotechn ology, Wiley VCH, New York NY, pp 856-853 a); ew York NY, unit 7.7 ...

[0110] A variety of PCR-based methods well known in the art can be used to extend the nucleic acid sequence encoding HTFS, utilizing partial nucleotide sequences, to extract upstream sequences such as promoters and regulatory elements. To detect. For example, one method utilizing the restriction site PCR method is to amplify an unknown sequence from genomic DNA in a cloning vector using common and nested primers (eg Sar
kar, G. (1993) PCR Methods Applic 2: 318-322). An alternative method using the inverse PCR method uses primers that extend in a wide range of directions and amplify unknown sequences from a circularized template. This template is derived from a restriction fragment containing known genomic loci and sequences surrounding it (see, eg, Triglia, T. et al. (1988) Nucleic Acids Res 16: 8186). The third method using the capture PCR method is human and yeast artificial chromosome DNA.
PCR amplification of DNA fragments flanking a known sequence of (eg, Lagerstrom, M. et al.
1991) PCR Methods Applic 1: 111-119). This method allows digestion and ligation with multiple restriction enzymes to insert the recombinant double-stranded sequence into a region of unknown sequence prior to PCR. It is also possible to obtain the unknown sequence using other methods well known in the art. (For example, Parker, JD, etc. (19
91) Nucleic Acids Res. 19: 3055-3060). Furthermore, by using PCR, nested primers, and PROMOTER FINDER library (Clontech, Palo Alto CA), genomic DN
Walking within A is possible. This method does not require screening the library and is useful for looking for intron / exon junctions. In all PCR-based methods, the primers are commercially available OLIGO 4.06 Primer Analysis softwar
Using e (National Biosciences, Plymouth MN) or another suitable program, the length is 22 to 30 nucleotides, the GC content is 50% or more, and about 68 ° C to 72 ° C.
Designed to anneal to the mold at a temperature of ° C.

When screening full-length cDNAs, it is preferable to use libraries whose size has been selected to contain large cDNAs. Furthermore, if the oligo d (T) library cannot produce a full-length cDNA, a randomly primed library, which often contains a sequence having the 5'region of the gene, is useful. Genomic libraries will be useful for extension of sequences into the 5'non-transcribed regulatory regions.

Sequencing or PCR using a commercially available capillary electrophoresis system
It is possible to analyze or confirm the size of the nucleotide sequence of the product. For more information,
Capillary sequencing uses a flowable polymer for electrophoretic separation, and a laser-activated fluorochrome specific for four different nucleotides and a CCD camera used to detect emitted wavelengths. It is possible.
The output / light intensity is determined by the appropriate software (eg GENOTYPER and SEQUENCE NAVIGA
TOR, PE Biosystems) and converted into electrical signals, and the process from sample loading to computer analysis and electronic data display are computer controllable. Capillary electrophoresis is particularly suitable for sequencing small pieces of DNA, which may be present in small amounts in a particular sample.

In another embodiment of the invention, the polynucleotide sequence encoding HTFS or a fragment thereof is cloned into a recombinant DNA molecule to express HTFS, a fragment thereof or a functional equivalent in a suitable host cell. It is possible. Due to the degeneracy of the genetic code, alternative DNA sequences may be produced which encode substantially the same or functionally equivalent amino acid sequences, which sequences are available for cloning and expression of HTFS.

The nucleotide sequences of the present invention can be recombined using methods commonly known in the art to alter the sequences encoding HTFS for various purposes. This purpose includes, but is not limited to, cloning, processing and / or regulating expression of the gene product. Nucleotide sequences can be recombined using mixing of DNA with random fragments or PCR reassembly of gene fragments and synthetic oligonucleotides. For example, oligonucleotide-mediated directed mutagenesis can be used to introduce mutations that create new restriction sites, alter glycosylation patterns, alter codon choices, create splice variants, and the like.

The nucleotides of the present invention were labeled with MOLECULAR BREEDING (Maxygen Inc., Santa Clara C
A; U.S. Pat.No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17: 793.
-797; Christians, FC et al. (1999) Nat. Biotechnol. 17: 259-264; Crameri, A.
Others (1996) Nat. Biotechnol. 14: 315-319) and the ability to shuffle using HTFS biological or enzymatic activity or to bind to other molecules or compounds. The biological properties of HTFS such as can be changed or improved. DNA shuffling is the process of creating a library of gene variants by recombination of gene fragments by the PCR method. The library is then selected or screened to identify genetic variants with the desired properties. These preferred variants are pooled and the DNA shuffling and selection / screening repeated. Therefore, a variety of genes are created by artificial breeding and rapid molecular evolution. For example, one gene fragment having mutations at random positions can be subjected to recombination, screening, and shuffling until the desired property is optimized. Alternatively, a fragment of a given gene may be recombined with a fragment of a homologous gene of the same gene family of the same or different species, thereby regulating the genetic diversity of multiple natural genes in a regulatable manner in accordance with the protocol. Can be maximized.

According to another embodiment, the sequences encoding HTFS can be synthesized in whole or in part using chemical methods well known in the art (eg, Caruthers. MH et al. (1980).
) Nucl. Acids Res. Symp. Ser 7: 215-223; and Horn, T. et al. (1980) Nucl. Acid
s Res. Symp. Ser. 225-232). Alternatively, chemical methods can be used to synthesize HTFS itself or fragments thereof. For example, peptide synthesis can be performed using various solid phase techniques (eg, Creighton, T. (1984) Proteins. Structures and Molecular Properties , WH Freeman, New York NY, pp. 55-60; Ro.
See berge, JY et al. (1995) Science 269: 202-204). Alternatively, automation of synthesis may be achieved using, for example, the ABI 431A Peptide Synthesizer (PE Biosystems).
In addition, the amino acid sequence of HTFS, or any portion thereof, may be modified by direct synthetic changes, and / or in combination with sequences from other proteins or any portion thereof using chemical methods to produce the native amino acid sequence. It is possible to produce a polypeptide having a polypeptide sequence or a variant polypeptide.

This peptide is used for preparative high performance liquid chromatography (eg, Chiez, RM).
And FZ Regnier (1990) Methods Enzymol. 182: 392-421)). The composition of the synthesized peptide can be confirmed by amino acid analysis or sequencing (see, for example, Creighton, supra, pp 28-53).

To express a biologically active HTFS, the nucleotide sequence encoding HTFS or a derivative thereof is inserted into a suitable expression vector. This expression vector contains the elements necessary for the regulation of transcription and translation of the coding sequence inserted into a suitable host. These elements include enhancers, constitutive and expression-inducible promoters in the vector and polynucleotide sequences encoding HTFS, and 5 ′.
And regulatory sequences such as the 3'untranslated region. Such elements vary in length and specificity. With a particular initiation signal, it is possible to achieve more efficient translation of sequences encoding HTFS. Such signals include the ATG initiation codon and nearby sequences such as the Kozak sequence. If the HTFS coding sequence and its initiation codon, upstream regulatory sequences were inserted into a suitable expression vector, no additional transcriptional or translational regulatory signals would be required. However, if only the coding sequence or a fragment thereof is inserted, an exogenous translational control signal containing an in-frame ATG initiation codon must be included in the expression vector. Exogenous translational elements and initiation codons can be obtained from a variety of natural and synthetic sources. The efficiency of expression can be increased by the inclusion of enhancers suitable for the particular host cell system used. (See, for example, Scharf, D. et al. (1994) Results Probl. Cell Differ. 201-18-162.)
.

Methods which are well known to those skilled in the art can be used to produce expression vectors containing sequences encoding HTFS and suitable transcriptional and translational regulatory elements. These methods include in vitro recombinant DNA technology, synthetic technology, and in vivo gene recombination technology. (For example, Sambrook, J. et al. (1989) Molecular Cloning. A Laboratory Manual , Cold Spring Harbor Press, Plainview NY, Chapters 4 and 8, and 16-17;
And Ausubel, FM et al. (1995) Current Protocols in Molecular Biology , Jo.
hn Wiley & Sons, New York NY, ch. 9 and 13-1-4).

A variety of expression vector / host systems may be utilized to retain and express sequences encoding HTFS. These include, but are not limited to, microorganisms such as recombinant bacteriophage, plasmids, or bacteria transformed with cosmid DNA expression vectors, yeast transformed with yeast expression vectors, and viral expression vectors. Insect cell lines infected with (eg, baculovirus), or plants transformed with viral expression vectors (eg, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or bacterial expression vectors (eg, Ti or pBR322 plasmids) Cell lines and animal cell lines are included (Sambrook, supra, Ausubel, Van Heeke, G. and SM Schuster (1989) J. Biol. Chem. 264: 550.
3-5509, Bitter, GA et al. (1987) Methods Enzymol. 153: 516-544; Scorer, CA
(1994) Bio / Technology 12:18 1-184; Engelhard, EK et al. (1994) Proc. N.
atl. Acad. Sci. USA 91: 3224-3227, Sandig, V. et al. (1996) Hum. Gene Ther. 7
: 1937-1945, Takamatsu, N. (1987) EMBOJ. 6: 307-311, Coruzzi, G. et al. (1984)
EMBOJ. 3: 1671-1680, Broglie, R. et al. (1984) Science 224: 838-843, Winter, J
Others (1991) Results Probl. Cell Differ. 17: 85-105, The McGraw Hill Yearbook of Science and Technology (1992) McGr
aw Hill New York NY, pp.191-196, Logan, J. and T. Shenk (1984) Proc. Nat
l. Acad. Sci. USA 81: 3655-3659, Harrington, JJ et al. (1997) Nat. Genet. 1
5: 345-355 etc.). Expression vectors derived from retroviruses, adenoviruses, herpesviruses or vaccinia viruses, or expression vectors derived from various bacterial plasmids can be used to deliver nucleotide sequences to target organs, tissues or cell populations (Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5 (6): 3
50-356, Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90 (13): 6340-6344, Bul.
ler, RM et al. (1985) Nature 317 (6040): 813-815; McGregor, DP et al. (1994) Mol.
Immunol. 31 (3): 219-226, Verma, IM and N. Somia (1997) Nature 389: 239.
-See 242). The present invention is not limited by the host cell used.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for the polynucleotide sequence encoding HTFS. For example, routine cloning, subcloning of a polynucleotide sequence encoding HTFS,
PBLUESCRIPT (Stratagene, La Jolla CA) or pSPORT1 plasmid (G
A multifunctional E. coli vector such as IBCO BRL) can be used. Ligation of the HTFS-encoding sequence into multiple cloning sites of the vector disrupts the lacZ gene, allowing a colorimetric screening method for identification of transformed bacteria containing recombinant molecules. In addition, these vectors can be used to generate in vitro transcription of cloned sequences, dideoxin screening, single-stranded rescue by helper phage, and nested deletions (e.g., V
See an Heeke, G. and SM Schuster (1989) J. Biol. Chem. 264: 5503-5509.
). For example, when a large amount of HTFS is required for antibody production, a vector that induces high level expression of HTFS can be used. For example, T5, which strongly induces expression
Alternatively, a vector containing the T7 bacteriophage promoter can be used.

It is possible to use yeast expression systems for the expression of HTFS. Various vectors containing constitutive or inducible promoters such as α-factor, alcohol oxidase and PGH promoter can be used for yeast Saccharomyces cerevisiae or Pichia pastoris . Furthermore, such vectors induce either the secretion of the expressed protein or its retention within the cell, integrating foreign sequences into the host genome for stable growth. (For example, Ausubel .; and Bitter, GA et al. (1987) Methods above.
Enzymol. 153: 51-794: Scorer. CA et al. (1994) Bio / Technology 121-181-184.
Plant systems can also be used to express HTFS. Transcription of the sequence encoding HTFS, for example, viral promoters such as 35S and 19S promoter from CaMV alone,
Alternatively, it is promoted in combination with an omega leader sequence from TMV (see, eg, Coruzzi, supra, Broglie, supra, Winter, supra). These products are direct
It can be introduced into plant cells by DNA transformation or transfection via pathogens. (See, eg, The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill NY, pp. 191-196).

In mammalian cells, a variety of virus-based expression systems may be utilized. When adenovirus is used as an expression vector, the HTFS coding sequence can be linked to an adenovirus transcript / translation complex consisting of a late promoter and a triple leader sequence. Insertion into the nonessential E1 or E3 region of the viral genome makes it possible to obtain live virus expressing HTFS in infected host cells (Logan, J.
And Shenk, T. (1984) Proc. Natl. Acad. Sci. 81: 3655-3659). In addition, transcription enhancers, such as the Rous Sarcoma Virus (RSV) enhancer, can be used to increase expression in mammalian host cells. For high level expression of proteins, SV40 or EBV based vectors can be used.

Human artificial chromosomes (HACs) can be used to supply larger fragments of DNA than those expressed on a plasmid and contained therein. HACs of about 6kb-10Mb for treatment
Are prepared and delivered by conventional delivery methods (liposomes, polycationic amino polymers, or vesicles). (For example, Harrington.JJ et al. (1997) Nat Genet. 15: 3.
45-355.).

For long-term production of recombinant proteins in mammalian systems, stable expression of HTFS in cell lines is desirable. For example, the expression vector can be used to transform a cell line with a sequence encoding HTFS. Such expression vectors contain replication and / or endogenous expression elements of viral origin and a selectable marker gene on the same or another vector. After the introduction of the vector, the cells are grown in enriched medium for about 1-2 days before being transferred to selective medium. The purpose of the selectable marker is to confer resistance to selective mediators, and its presence allows growth and recovery of cells which reliably express the introduced sequences. Resistant clones of stably transformed cells can be propagated using tissue culture techniques suitable for that cell type.

[0126] Any number of selection systems can be used to recover transformed cell lines. The selection systems include, but are not limited to, include herpes simplex virus thymidine kinase gene and adenine phosphoribosyltransferase genes, respectively tk ^- or apr ^- used in the cell. (For example, Wigler, M. et al. (1
977) Cell 11: 223-232; and Lowy, I. et al. (1980) Cell 22: 817-823). Also, resistance to antimetabolites, antibiotics or herbicides can be used as the basis for selection. For example, dhfr confers resistance to methotrexate, neo confers resistance to aminoglycosid neomycin and G-418, and als or pat confers resistance to chlorsulfuron (cHTFSsulfuron) and phosphinotricin acetyltransferase (eg, phosphinotricin acetyltransferase). , Wigl
er, M. et al. (1980) Proc. Natl. Acad. Sci. 77: 3567-3570; Colbere-Garapin,
F. et al. (1981) J. Mol. Biol. 150: 1-14). Further genes available for selection have been described in the literature, eg trpB and hisD which alter what the cell needs for metabolism (eg Hartman, SC and RC Mulligan (1988) Proc. Natl. Acad.
. Sci. 85: 8047-51). Anitocyanin, green fluorescent protein (GFP; Clon
tech), β-glucuronidase and its substrate GUS, luciferase and its substrate luciferin and other visible markers are used. Green fluorescent protein (GFP) (Clon
tech, Palo Alto, CA) can also be used. These markers can be used not only to identify transformants, but also to quantify transient or stable protein expression due to a particular vector system (eg, Rhodes, CA et al. (19
95) Methods Mol. Biol. 55: 121-131).

Even if the presence / absence of expression of the marker gene indicates the presence of the gene of interest, it may be necessary to confirm the presence and expression of the gene. For example, if the sequence encoding HTFS is inserted within a marker gene sequence, transformed cells containing the sequence encoding HTFS can be identified by the lack of marker gene function.
Alternatively, the marker gene can be placed in tandem with the sequence encoding HTFS under the control of one promoter. Expression of the marker gene in response to induction or selection usually also indicates expression of the tandem gene.

In general, host cells which contain a nucleic acid sequence encoding HTFS and which express HTFS can be identified using a variety of methods well known to those of skill in the art. These methods include
Protein biological tests or immunological methods including DNA-DNA or DNA-RNA hybridization, PCR methods, membrane-based, solution-based, or chip-based techniques for detection and / or quantification of nucleic acids or proteins. Assay included,
It is not limited to these.

HT with either specific polyclonal or monoclonal antibodies
Immunological methods for detecting and measuring the expression of FS are well known in the art. Such techniques include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescence activated cell sorter (FACS), and the like. Two-site, monoclonal-based immunoassay using a monoclonal antibody that reacts with two non-interfering epitopes on HTFS
Is preferred, but competitive binding assays can also be used. These and other assays are well known in the art. (For example, Hampton. R
Et al. (1990) Serological Methods, a Laboratory Manual. APS Press. St Paul
.MN, Sect. IV; Coligan, JE et al Current Protocols in Immunology , Greene
Pub. Associates and Wiley-Interscience, New York. NY; and Pound, JD (
1990) Immunochemical Protocols , Humans Press, Totowa NJ).

Various labeling and conjugation techniques are well known to those of skill in the art and can be used in various nucleic acid and amino acid assays. Methods for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HTFS include oligo labeling, nick translation, end labeling, or labeled nucleotides. Includes the PCR amplification used. Alternatively, the HTFS coding sequence, or any fragment thereof, can be cloned into a vector to generate an mRNA probe. Such vectors, which are well known in the art and are commercially available, can be used for the synthesis of RNA probes in vitro by the addition of a suitable RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. . These methods are described, for example, in Amersham Pharmac
ia Biotech and Promega (Madison WI), US Biochemical Corp (Cleveland OH
) Can be used with various kits commercially available. Suitable reporter molecules or labels that can be used for easy detection include substrates, cofactors, inhibitors, magnetic particles, and radionuclides, enzymes, fluorescent agents, chemiluminescent agents, chromogenic agents and the like.

Host cells transformed with a nucleotide sequence encoding HTFS are cultured under conditions suitable for the expression and recovery of this protein in cell culture. Whether the protein produced by a transformed cell is secreted or remains intracellular depends on the sequence and / or the vector used. It will be understood by those skilled in the art that the expression vector containing the polynucleotide encoding HTFS can be designed to contain a signal sequence that induces the secretion of HTFS which penetrates the prokaryotic cell membrane and the eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to regulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Modifications of such polypeptides include acetylation, carboxylation, glycosylation, phosphorylation, lipidation (
lipidation), and acylation, but is not limited thereto.
Post-translational processing which cleaves a "prepro" or "pro" form of the protein can be used to identify target proteins, folds and / or activities. Different types of host cells (eg, CHO, HeLa, MDCK, MEK293, WI38) with specific cellular machinery and characteristic mechanisms for post-translational activity
It is available from the Collection (ATCC; Bethesda, MD) and is selected to ensure the correct modification and processing of foreign proteins.

In another embodiment of the invention, the natural or altered or recombinant nucleic acid sequence encoding HTFS is linked to a heterologous sequence which results in translation of the fusion protein of any of the host systems described above. For example, a chimeric HT containing a heterologous moiety that can be recognized by a commercially available antibody
The FS protein may facilitate the screening of peptide libraries for inhibitors of HTFS activity. In addition, the heterologous protein portion and the heterologous peptide portion are
Commercially available affinity substrates can be used to facilitate purification of the fusion protein. Such parts include glutathione S transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-Hi.
s, FLAG, c-mc, hemagglutinin (HA), but are not limited thereto. GST and MBP, Trx, CBP, 6-His immobilized glutathione, maltose, phenylarsine oxide, calmodulin,
Each of the metal chelate resins allows purification of the cognate fusion protein. FLAG
, C-mc, and hemagglutinin (HA) allow purification of the immunoaffinity of the fusion protein using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. Alternatively, HTFS can be cleaved from the heterologous moiety after purification by genetically engineering the fusion protein to include a proteolytic cleavage site between the HTFS coding sequence and the heterologous protein sequence. Methods for expressing and purifying fusion proteins are described in Ausubel. (1995, supra ch 10). A variety of commercially available kits can be used to facilitate expression and purification of the fusion protein.

In another embodiment of the invention, it is possible to synthesize radiolabeled HTFS in vitro using the TNT rabbit reticulocyte lysate or wheat germ extraction system (Promega). These systems connect transcription and translation of sequences encoding proteins that are operably linked to the T7 or T3, SP6 promoters. Translation occurs in the presence of a radiolabeled amino acid precursor, which is, for example, ³⁵ S methionine.

[0135] The HTFS of the present invention or a fragment thereof can be used to screen for compounds that specifically bind to HTFS. HT with at least one or more test compounds
It is possible to screen for specific binding to FS. Examples of test compounds include antibodies, oligonucleotides, proteins (eg receptors) or small molecules.

In one example, the compound thus identified is intimately linked to the natural ligand of HTFS, eg, the ligand or fragment thereof, or the natural substrate, structural or functional mimetic or natural binding partner. are related (Coligan, see Chapter 5, etc. of JE other (1991) Curr ent Protocols in Immunology 1 (2)). Similarly, the compound is HTFS
May be closely related to the natural receptor to which it binds, or at least some fragment of the receptor, eg, the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one example, screening for such compounds involves making suitable cells that express HTFS as either a secreted protein or a protein on the cell membrane. Suitable cells include mammals,
Cells from yeast, E. coli are included. Cells expressing HTFS or cell membrane fragments containing HTFS are contacted with a test compound and binding, stimulation or inhibition of either HTFS or the compound is analyzed.

Certain assays may simply experimentally bind the test compound to the polypeptide and detect binding with a fluorophore, radioisotope, enzyme conjugate or other detectable label. For example, this assay comprises binding at least one test compound to HTFS in solution or immobilized on a solid support,
The step of detecting binding of HTFS to this compound may be included. Alternatively, detection and measurement of binding of the test compound in the presence of labeled competitor can be performed. In addition, this assay can be performed with cell-releasing agents, chemical libraries or natural product mixtures, where the test compound is released in solution or immobilized on a solid support.

The HTFS of the present invention or fragments thereof can be used to screen for compounds that modulate the activity of HTFS. Such compounds include agonists, antagonists, partial or inverse agonists and the like. In one embodiment, HTFS
Is bound to at least one test compound, the assay is performed under conditions permitting the activity of HTFS, and the activity of HTFS in the presence of the test compound is HT in the absence of the test compound.
Compare with the activity of FS. A change in the activity of HTFS in the presence of the test compound suggests the presence of compounds that modulate the activity of HTFS. Alternatively, the assay is performed by binding the test compound to an in vitro or cell free system containing HTFS under conditions suitable for the activity of HTFS. In any of these assays, the test compound that modulates the activity of HTFS can bind indirectly and need not come into direct contact with the test compound. At least one and more than one test compound can be screened.

In another example, homologous recombination in embryonic stem cells (ES cells) is used to "knock out" a polynucleotide encoding HTFS or a mammalian homologue thereof in an animal model system. Such techniques are well known in the art and are useful in the production of animal models for human disease (see, eg, US Pat. Nos. 5,175,383 and 5,767,337). Mouse ES cells, such as the 129 / SvJ cell line, are derived from early mouse embryos and can be grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted with a marker gene such as the neomycin phosphotransferase gene (neo: Capecchi, MR (1989) Science 244: 1288-1292). This vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively,
Homologous recombination is performed using the Cre-loxP system to knock out the target gene in a tissue-specific or developmental stage-specific manner (Marth, JD (1996) Clin. Invest. 97: 1999-2002;
Wagner, KU et al. (1997) Nucleic Acids Res. 25: 4323-43 30). Transformed
ES cells are identified and microinjected into mouse cell blastocysts collected from, for example, the C57BL / 6 mouse line. Blastocysts are surgically introduced into pseudopregnant females, the inherited traits of the resulting chimeric progeny are determined and crossed to create a heterozygous or homozygous system.
The transgenic animals thus produced can be tested for potential therapeutic or toxic agents.

Polynucleotides encoding HTFS can be engineered in vitro in human blastocyst-derived ES cells. Human ES cells have the potential to differentiate into at least eight distinct cell lineages, including endoderm, mesoderm and ectoderm cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages and cardiomyocytes (Thomso
n, JA et al. (1998) Science 282: 1145-1 147).

The HTFS-encoding polynucleotides can be used to generate “knock-in” humanized animals (pigs) or transgenic animals (mouse or rat) that model human disease. Using knock-in technology, a region of a polynucleotide encoding HTFS is injected into animal ES cells and the injected sequences are integrated into the animal cell genome. The transformed cells are injected into the blastula and the blastula is transplanted as described above. Studying transgenic offspring or inbreds, treating with potential drugs,
Get information on the treatment of human diseases. Alternatively, mammalian inbred strains that overexpress HTFS, eg, secrete HTFS into milk, can be a convenient source of protein (
Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4: 55-74).

Treatment There are chemical and structural similarities between a region of HTFS and a region of human transferase, eg in the context of sequences and motifs. In addition, HTFS expression is associated with proliferative tissues and inflammation. Therefore, HTFS is thought to play a role in abnormal cell proliferation and diseases of the immune system. In treating diseases associated with increased HTFS expression or activity, it is desirable to reduce HTFS expression or activity. In addition, in the treatment of diseases associated with decreased HTFS expression or activity, it is desirable to increase HTFS expression or activity.

Thus, in one embodiment, a patient may be administered HTFS or a fragment or derivative thereof for the treatment or prevention of diseases associated with decreased expression or activity of HTFS. Such disorders include, but are not limited to, cell proliferative disorders and disorders of the immune system, including cell keratosis and actinic atherosclerosis, bursitis, and bursitis. Dysplasia, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and adenocarcinoma and leukemia, lymphoma, melanoma, myeloma , Sarcoma, and teratocarcinoma, specifically adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gallbladder, ganglion, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid gland. , Cancer of the penis, prostate, salivary gland, skin, testis, thymus, thyroid, and uterus, among which diseases of the immune system are inflammation and actinic keratosis,
Acquired immune deficiency syndrome (AIDS) and adrenal insufficiency, adult respiratory distress syndrome, allergy, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, self Immune thyroiditis, bronchitis, bursitis,
Cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes, emphysema, erythroblastosis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto thyroid gland Inflammation, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, lymphotoxin-induced temporary lymphopenia, mixed connective tissue disease (MCTD), multiple sclerosis , Myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome , Systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, cancer complications, hemodialysis, extracorporeal circulation, external , And lymphoma, hematopoietic cancers, including leukemia, myelomas.

In another embodiment, HTFS or a fragment or derivative thereof is expressed for the treatment or prevention of diseases associated with decreased expression or activity of HTFS, including but not limited to the diseases listed above. It is also possible to administer the resulting vector to a patient.

In yet another embodiment, substantially purified HTFS is used for the treatment or prevention of diseases associated with decreased expression or activity of HTFS, including but not limited to the diseases listed above. It is also possible to administer the composition containing it to a patient with a suitable pharmaceutical carrier.

In yet another embodiment, an agonist that modulates the activity of HTFS for the treatment or prevention of diseases associated with decreased expression or activity of HTFS, including but not limited to the diseases listed above. It is also possible to administer to a patient.

In a further embodiment, a patient may be administered an antagonist of HTFS for the treatment or prevention of disorders associated with increased HTFS expression or activity. Examples of such diseases include, but are not limited to, the above-mentioned abnormal cell proliferation diseases and immune system diseases. In one embodiment, an antibody that specifically binds HTFS can be used directly as an antagonist or indirectly as a targeting or delivery mechanism to deliver the drug to cells or tissues that express HTFS.

In another example, the complementary sequence of a polynucleotide encoding HTFS for the treatment or prevention of diseases associated with increased expression or activity of HTFS, including but not limited to the diseases listed above. It is also possible to administer a vector that expresses

In another example, any of the proteins, antagonists, antibodies, agonists, complementary sequences, vectors of the invention can be administered in combination with another suitable therapeutic agent. One of ordinary skill in the art can select suitable therapeutic agents for use in the combination therapy according to conventional pharmaceutical principles. The combination with therapeutic agents may bring about a synergistic effect in the treatment or prevention of the various diseases listed above. Using this method, it is possible to achieve a medicinal effect with a small amount of each drug, and it is possible to reduce the possibility of a wide range of side effects.

HTFS antagonists can be prepared using methods common in the art. More specifically, purified HTFS can be used to produce antibodies, and therapeutic drug libraries can be screened to identify those that specifically bind to HTFS. HTFS
Antibodies can also be produced using a method generally used in this field. Such antibodies include polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chains,
Fab fragments and fragments produced by Fab expression libraries are included. However, it is not limited to these. For treatment, neutralizing antibodies (ie,
Those which inhibit the formation of dimers) are particularly preferred.

For the production of antibodies, various hosts, including goats, rabbits, rats, mice, humans and others, are injected with HTFS or any fragment, or oligopeptide thereof with immunogenic properties. Can be immunized with. Depending on the host species, various adjuvants may be used to enhance the immune response. Such adjuvants include Freund's adjuvant, mineral gel adjuvants such as aluminum hydroxide, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and surfactants such as dinitrophenol. However, it is not limited thereto. Among the adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are particularly preferable.

Oligopeptides, peptides or fragments used to raise antibodies to HTFS are preferably composed of at least about 5 amino acids, generally about 10 or more amino acids. These oligopeptides or peptides, or fragments thereof, are preferably identical to a part of the amino acid sequence of the natural protein. Short stretches of HTFS amino acids can be fused with sequences of another protein, such as KLH, to produce antibodies to the chimeric molecule.

Monoclonal antibodies against HTFS can be produced by any cell line in culture, using any technique which produces antibody molecules. These techniques include, but are not limited to, hybridoma technology, human B cell hybridoma technology, and EBV-hybridoma technology (eg, Kohler,
G. et al. (1975) Nature 256: 495-497; Kozbor, D. et al. (1985) .J. Immunol. Met.
hods 81-8-42; Cote, RJ et al. (1983) Proc. Natl. Acad. Sci. 80: 2026-2030.
Cole, SP et al. (1984) Mol. Cell Biol. 62: 109-120).

In addition, techniques such as splicing the mouse antibody gene onto the human antibody gene developed to produce “chimeric antibodies” are used to obtain molecules with suitable antigen specificity and biological activity ( For example, Morrison, SL et al. (1984) Proc. N
atl. Acad. Sci. 81-4851-4855; Neuberger, MS et al. (1984) Nature 312: 604.
-608; Takeda, S. et al. (1985) Nature 314: 452,454). Alternatively, applying the described techniques for the production of single chain antibodies using methods well known in the art,
Generates HTFS specific single chain antibody. Antibodies with related specificities but of different idiotypic composition can also be generated by chain mixing from random combinatorial immunoglobulin libraries (eg, Burton DR (1991) Proc. Natl. A).
cad. Sci. 88: 11120-3).

Antibodies can be induced by in vivo production in a population of lymphocytes, or by screening immunoglobulin libraries or a panel of highly specific binding reagents, as shown in the literature. (See, for example, Orlando, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833.
-3837; Winter, G. et al. (1991) Nature 349: 293-299).

Antibodies containing specific binding sites for HTFS can also be produced. For example,
Such fragments include F (ab ') fragments produced by pepsin digestion of antibody molecules and Fabs produced by reducing the disulfide bridges of the fragments to F (ab').
Fragments are included, but are not limited to. Alternatively, generating a Fab expression library allows for rapid and easy identification of monoclonal Fab fragments with the desired specificity (eg, Huse, WD et al. (1989) Science 254: 12.
See 75-1281).

A variety of immunoassays are used to screen to identify antibodies with the desired specificity. Numerous protocols for competitive binding, or immunoradioactivity, using either polyclonal or monoclonal antibodies with isolated specificity are well known in the art. Usually HTFS for such immunoassays
Included is the measurement of complex regulation between the antibody and its specific antibody. Two-site monoclonal-based immunoassays are generally used with monoclonal antibodies reactive to two non-interfering HTFS epitopes, but competitive binding assays can also be used (Pound, supra).

Using various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques, H 2
Assess the affinity of the antibody for TFS. The affinity is represented by a binding constant Ka, which is a value obtained by dividing the molar concentration of the HTFS antibody complex by the molar concentration of the free antibody and the free antigen under equilibrium. Ka of a polyclonal antibody drug having a heterogeneous affinity for many HTFS epitopes represents the average affinity or binding activity of the antibody for HTFS. Ka of a monoclonal antibody drug specific for a specific HTFS epitope is
Represents a true measure of affinity. The high affinity antibody drug having a Ka value of 10 ⁹ to 10 ¹² L / mol is preferably used in an immunoassay in which the HTFS antibody complex must withstand violent manipulation. The low affinity antibody drug having a Ka value of 10 ⁶ to 10 ⁷ L / mol is
Immunopurification that requires HTFS to finally dissociate from the antibody in an activated state (immunopuri
fication) and similar processes. (Catty, D. (1988) Antibodies , Volume I: A Practical Approach .IRL Press, Washington, DC; Liddell,
JE and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies , J
ohn Wiley & Sons, New York NY).

To study the quality and suitability of such pharmaceuticals in certain downstream applications,
The antibody titer and binding activity of the polyclonal antibody drug are further evaluated. For example, a polyclonal antibody drug containing at least 1-2 mg / ml of the specific antibody, preferably 5-10 mg / ml of the specific antibody, is generally used in the treatment in which the HTFS antibody complex must be precipitated. Specificity of antibodies and antibody titer, binding activity, quality of antibodies and guidelines for usage in various applications are publicly available. (For example, Cat
ty, supra, and Coligan et al., supra).

In another embodiment of the invention, the polynucleotide encoding HTFS, or any fragment or complementary sequence thereof, can be used for therapeutic purposes. In one embodiment,
Gene expression can be altered by designing sequences or antisense molecules (DNA and RNA, modified nucleotides) complementary to the coding region and regulatory region of the gene encoding HTFS. Such techniques are well known in the art, and sense or antisense oligonucleotides or large fragments can be designed from the control region of the HTFS coding sequence, or from various positions along the coding region (as an example). , Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Tot
awa NJ).

When used in therapy, any gene delivery system suitable for introducing antisense sequences into suitable target cells can be used. Antisense sequences can be delivered intracellularly in the form of expression plasmids that, upon transcription, express sequences complementary to at least a portion of the cellular sequences encoding the target protein (eg, Slater, JE et al.
(1998) J. Allergy Clin. Immunol. 102 (3): 469-475; and Scanlon, KJ et al. (1
995) 9 (13): 1288-1296.). The antisense sequence can also be introduced into cells using a viral vector such as a retrovirus or an adeno-associated viral vector (for example, Miller, AD (1990) Blood 76: 271; Ausubel,
Supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63 (3): 323-347). Other genetic delivery mechanisms include liposomal systems, artificial viral envelopes, and other systems known in the art (Rossi, JJ (1995) Br. Med.
Bull. 51 (1): 217-225; Boado, RJ et al. (1998) J. Pharm. Sci. 87 (11): 1308-1.
315; and Morris, MC et al. (1997) Nucleic Acids Res. 25 (14): 2730-2736.).

In another embodiment of the invention, the polynucleotides encoding HTFS can be used for somatic or germ cell gene therapy. Gene therapy includes (i) gene deficiency (for example, X chromosome linked inheritance (Cavazzana-Calvo, M. et al. (2000) Scie.
nce 288: 669-672). Severe combined immunodeficiency (SCID) -X1)
, Hereditary adenosine-deaminase (ADA) deficiency (Blaese, RM et al. (1995) Sci
ence 270: 475-480; Bordignon, C. et al. (1995) Science 270: 470-475), severe combined immunodeficiency, cystic fibrosis (Zabner, J. et al. (1993) Cell 75: 207-). 216
: Crystal, RG and others (1995) Hum. Gene Therapy 6: 643-666; Crystal, RG and others
. (1995) Hum. Gene Therapy 6: 667-703), thalassamia, familial hypercholesterolemia, hemophilia due to factor VIII or factor IX deficiency (Crys
tal, 35 RG (1995) Science 270: 404-410; Verma, IM and Somia. N. (199
7) Nature 389: 239-242), (ii) expressing a conditionally lethal gene product (eg, in the case of cancer due to uncontrolled cell growth), and (iii) intracellular parasites. (For example, human immunodeficiency virus (HIV) (Baltimore, D. (1988) Natu
re 335: 395-396; Poescbla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11.
395-11399), hepatitis B or C virus (HBV, HCV), Candida albicans
And a protein having a protective function against fungal parasites such as Paracoccidioides brasiliensis , Plasmodium falciparum, and protozoan parasites such as Trypanosoma cruzi ). When a gene deficiency required for the expression or regulation of HTFS causes a disease, HTFS can be expressed from a suitable population of introduced cells to alleviate the symptoms caused by the gene deficiency.

In a further embodiment of the present invention, diseases and disorders due to HTFS deficiency are produced by preparing mammalian expression vectors encoding HTFS and applying these vectors by mechanical means.
Treat by introducing into HTFS-deficient cells. Mechanical transfer techniques used for cells in vivo or in vitro include (i) microinjection of DNA into individual cells, (ii) implantation of gold particles, (iii) liposome-mediated transfection, (iv) ) Receptor-mediated gene transfer, and (v) DNA transposons (Morgan
, RA and WF Anderson (1993) Annu. Rev. Biochem. 62: 191-217; Ivics, Z.
. (1997) Cell 91: 501-510; Boulay, JL. And H. Recipon (1998) Curr. Opin
Biotechnol. 9: 445-450).

Expression vectors that can affect the expression of HTFS include, but are not limited to:
PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vector (Invitrogen, Carlsbad CA)
, PCMV-SCRIPT, PCMV-TAG, PEGSH / PERV (Stratagene, La Jolla CA), PTET-OFF
, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). In order to express HTFS, (i) a constitutively active promoter (for example, cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin gene), (ii) an inducible promoter (for example, a tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. contained in a commercially available T-REX plasmid (Invitrogen)).
Natl. Acad. Sci. USA 89: 5547-5551; Gossen, M. et al. (1995) Science 268: 1.
766-1769; Rossi, FMV and HM Blau (1998) Curr. Opin. Biotechnol. 9: 4
51-456)), ecdysone inducible promoter (commercially available plasmid PVGRXR
And PIND: Invitrogen), FK506 / rapamycin inducible promoter, or RU486 / mifepristone inducible promoter (Rossi, FMV a
nd HM Blau, supra), or (iii) the natural or tissue-specific promoter of the endogenous gene encoding HTFS from a normal individual can be used.

Commercially available liposome transformation kits (eg PERFEC sold by Invitrogen)
T LIPID and TRANSFECTION KIT) allows one of skill in the art to introduce polynucleotides into target cells in culture without much reliance on experience. Alternatively, the calcium phosphate method (Graham. FL and AJ Eb (1973) Virology 52: 456-
467) or electroporation (Neumann, B. et al. (1982) EMBO J. 1: 841-845). These standard mammalian transfection protocols need to be modified to introduce DNA into primary cells.

In another embodiment of the present invention, the disease or disorder caused by the gene deficiency associated with the expression of HTFS is controlled by (i) the retroviral terminal repeat (LTR) promoter or an independent promoter. An encoding polynucleotide, (ii) a suitable RNA packaging signal, and (iii) additional retrovirus
Retroviral vectors consisting of a cis-acting RNA sequence and a Rev responsive element (RRE) with the coding sequences necessary for efficient vector growth can be made and treated. Retroviral vectors (eg PFB and PFB NEO) are Str
Publicly available data (Riviere, I. et al. (1995) Proc. Na.
tl. Acad. Sci. USA 92: 6733-6737). Reference to the above data is made a part of this specification. This vector is compatible with VSVg (Armentano, D. et al.
(1987) J. Virol. 61: 1647-1650; Bender, MA et al. (1987) J. Virol. 61: 1639
-1646; Adam, MA and AD Miller (1988) J. Virol. 62: 3802-3806; Dull, T
Others (1998) J. Virol. 72: 8463-8471; Zufferey, R. Others (1998) J. Virol. 72:
9873-9880) or a suitable vector-producing cell line (VPCL) expressing a promiscuous envelope protein or an envelope gene having an affinity for the receptor on the target cell. No. 5,910,434 to RIGG ("Met
hod for obtaining retrovirus packaging cell lines producing high transdu
cing efficiency retroviral cytos "), a method for obtaining a retroviral packaging cell line is disclosed and incorporated herein by reference. Propagation of retroviral vectors, certain cell populations (eg CD
Transduction of (4 ⁺ T cells) and methods of returning the transduced cells to the patient are well known in the field of gene therapy and have been described in numerous references (Ranga, U. et al. (1997).
J. Virol. 71: 7020-7029; Bauer, G. et al. (1997) Blood 89: 2259-2267; Bonyhad.
i, ML (1997) J. Virol. 71: 4707-4716; Ranga, U. et al. (1998) Proc. Natl. A
cad. Sci. USA 95: 1201-1206: Su, L. (1997) Blood 89: 2283-2290).

Alternatively, an adenovirus-based gene therapy delivery system is used to deliver a polynucleotide encoding HTFS to cells having one or more genetic abnormalities associated with the expression of HTFS. The production and packaging of adenovirus-based vectors is well known in the art. Replication-defective adenovirus vectors have been shown to be variable for introducing genes encoding immunomodulatory proteins into intact pancreatic islets (Csete, ME et al. (1995) Transplantation 27: 263-268). A potential adenovirus vector has been described in US Pat. No. 5,707,618 ("Adeno
virus vectors for gene therapy "), which is incorporated herein by reference. For adenovirus vectors, see also Antinozzi, P
.A. Et al. (1999) Annu. Rev. Nutr. 19: 511-544; and Verma, IM and N. Somia
(1997) Nature 18: 389: 239-242, which is incorporated herein by reference.

Alternatively, a herpes-based gene therapy delivery system may be used to correlate 1 with the expression of HTFS.
Alternatively, a polynucleotide encoding HTFS is delivered to a target cell having multiple genetic abnormalities. Herpes simplex virus (HSV) -based vectors are of particular importance in introducing HTFS into HSV-affected central neurons. The construction and packaging of herpes-based vectors is well known in the art. Replication-competent herpes simplex virus (HSV) type I-based vectors have been used to deliver reporter genes to the primate eye (Liu, X. et al. (1999) Exp. Eye Res. 169: 385. -395). The production of HSV-1 viral vectors is described in US Pat. No. 5,804,413 (Herpes simplex virus swa
ins for gene transfer), which is incorporated herein by reference. U.S. Pat.No. 5,804,413, for purposes including human gene therapy,
There is a description of recombinant HSV d92 consisting of a genome containing at least one endogenous gene that is introduced into cells under the control of a suitable promoter. The patent also discloses methods of making and using recombinant HSV strains that are removed for ICP4, ICP27 and ICP22. For HSV vector, Goins, WF et al. (1999)
73: 519-532 and Xu, H. et al. (1994) Dev. Biol. 163: 152-161, incorporated herein by reference. Manipulation of cloned herpesvirus sequences, passage of recombinant virus after transfection of multiple plasmids containing different parts of the giant herpesvirus genome, growth and multiplication of herpesvirus, and transfer of herpesvirus cells. Infection is a technique well known in the art.

Alternatively, an alphavirus (positive single-stranded RNA virus) vector is used to deliver a polynucleotide encoding HTFS to target cells. Extensive biological research on the prototype α virus, Semliki Forest Virus (SFV), revealed that the gene transfer vector is based on the SFV genome (Garoff , H. and K.-J. Li (1998) Cun. Opin. Bi
otech. 9: 464-469). During replication of alphavirus RNA, subgenomic RNA that normally encodes the viral capsid protein is produced. Because this subgenomic RNA replicates at higher levels than full-length genomic RNA, capsid proteins are overproduced over viral proteins with enzymatic activity (eg, proteases and polymerases). Similarly, by introducing the HTFS coding sequence into the capsid coding region of the alphavirus genome, a large number of
RNA encoding HTFS is produced and HTFS is synthesized at high levels. Alphavirus infection is usually associated with cell lysis within 2-3 days, but Sindbis virus (SIN
The ability to establish a persistent infection of normal kidney cells (BHK-21) in hamsters carrying a mutant of (a) can be favorably altered so that lytic replication of alphavirus can be applied to gene therapy. (Dryga, SA et al. (1997) Virol
ogy 228: 74-83). Since α virus can be introduced into various hosts, HTFS can be introduced into various types of cells. Specific transduction of a subset of cells in a population may require sorting of cells prior to transduction. Manipulation of alpha virus infectious cDNA clones, alpha virus cDNA and RNA transfection, and alpha virus infection methods are well known in the art.

[0170] For example, it is possible to inhibit the expression of a gene by using an oligonucleotide derived from the transcription start site from about -10 to about +10 from the start site. Similarly,
It can be inhibited using triple helix base pairing. The triple helix structure is useful because it prevents the double helix from expanding sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances with triplex DNA have been described in the literature (eg Gee, JE et al. (1994) In: Huber, BE and BI Car.
r, Molecular and ImmunologiHTFSproaches , Futura Publishing Co., Mt. Kisc
o, NY). Complementary sequences or antisense molecules can also be designed to block translation of mRNA by blocking the binding of transcripts to ribosomes.

Ribozymes, enzymatic RNA molecules, can be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by nucleotide strand scission.
For example, recombinant hammerhead ribozyme molecules that specifically and effectively catalyze nucleotide scission of sequences encoding HTFS are included.

A specific ribozyme cleavage site within any potential RNA target is followed by the sequence GUA.
, GUU, and GUC, are first identified by scanning the target molecule against ribozyme cleavage sites. To evaluate, once identified, a short RNA sequence of 15 to 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site for secondary structural features that impair the function of the oligonucleotide. Is possible. The suitability of candidate targets can also be assessed by testing their ease of hybridization with complementary oligonucleotides using a ribonuclease protection assay.

Complementary ribonucleic acid molecules and ribozymes of the invention can be made for the synthesis of nucleic acid molecules using methods well known in the art. These methods include methods of chemically synthesizing oligonucleotides such as solid phase phosphoramidite compounds. Alternatively, RNA molecules may be generated in vitro and in vivo by transcription of a DNA sequence encoding HTFS, such DNA sequences using various RNA vector promoters, such as T7 or SP6, of various vectors. Can be incorporated into. Alternatively, these cDNA constructs that synthesize complementary RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

Modification of RNA molecules can increase intracellular stability and prolong half-life. Possible modifications include the addition of flanking sequences at the 5'and / or 3'ends of the molecule, or the use of phosphorothionate or 2'O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. However, it is not limited thereto. Unique to PNA production, this concept is that adenine, cytidine, guanine, thymine, which are not readily recognized by endogenous endonucleases,
And the acetyl-, methyl-, thio-, and similar modified forms of uridine, as well as the inclusion of non-conventional bases such as inosine, queosine, and wybutosine, in whole of these molecules. Can be expanded to.

A further embodiment of the invention includes a method of screening for compounds effective in altering the expression of a polynucleotide encoding HTFS. Compounds effective in altering expression of a particular polynucleotide include, but are not limited to, non-polymeric chemicals, oligonucleotides, antisense oligonucleotides, triple helix-forming oligos capable of interacting with a particular polynucleotide sequence. Nucleotides, transcription factors and other polypeptide transcriptional regulators are included. Effective compounds may act as inhibitors or enhancers of polynucleotide expression and alter expression of the polynucleotide. Therefore, in the treatment of diseases associated with increased HTFS expression or activity, compounds that specifically inhibit the expression of HTFS-encoding polynucleotides are therapeutically useful, and are associated with decreased HTFS expression or activity. In the treatment of disease,
Compounds that specifically enhance the expression of polynucleotides encoding HTFS may be therapeutically useful.

At least one can be tested for efficacy of altering expression of a particular polynucleotide.
From one to a plurality of test compounds can be screened. The test compound is
It can be obtained by any method known in the art including chemical modification of effective compounds.
Such methods are based on the chemical and / or structural properties of the target polynucleotide when it alters the expression of the polynucleotide, when selected from commercially available or proprietary natural or unnatural compound libraries. It is useful for rationally designing compounds and for selecting from libraries of combinatorially or randomly generated compounds. A sample containing a polynucleotide encoding HTFS is obtained by exposure to at least one test compound. The sample can include, for example, intact cells, permeabilized cells, in vitro cell release systems or reconstituted biochemical systems. Changes in expression of a polynucleotide encoding HTFS are assayed by any method known in the art. Usually, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding HTFS. The yield of hybridization is quantified and that value can be the basis for comparison of expression of polynucleotides exposed and unexposed to one or more test compounds. If an alteration in the expression of the polynucleotide exposed to the test compound is detected, it indicates that the test compound is effective in altering the expression of the polynucleotide. To examine the compound effective to changes in the expression of a specific polynucleotide, eg Schizosaccharomyces PomB e gene expression system (Atkins, D. et al. (1999) U.S. Pat. No. 5,932,435, Arndt, GM
(2000) Nucleic Acids Res. 28: E15) or human cell lines such as HeLa cells (Clark
e, ML et al. (2000) Biochem. Biophys. Res. Commun. 268: 8-13). Certain embodiments of the invention include screening combinatorial libraries of individual oligonucleotides (deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against specific polynucleotide sequences (Bruice , TW et al. (1997) US Pat. No. 5,686,242, Bruice, TW et al. (2000) US Pat. No. 6,022,691).

[0177] vectors available are a number of ways of introducing into a cell or tissue, in vivo, are equally suitable for use in in vitr o, and ex vivo. For ex vivo treatment, the vector is introduced into hepatocytes taken from a patient and cloned and propagated for autologous transplant back into the same patient. Transfection, ribosome injection or delivery by polycationic aminopolymers can be performed using methods well known in the art (eg Goldman, CK et al. (1997) Nature Biotechnology 15: 462.
-66 :).

Any of the above methods of treatment can be applied to any subject in need of treatment including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits and monkeys.

Another embodiment of the present invention relates to the administration of a pharmaceutical or sterile composition in association with a pharmaceutically acceptable carrier for all of the above mentioned therapeutic effects. Excipients include, for example, sugar,
Includes starch, cellulose, gums, and proteins. A variety of formulations are commonly known and the latest version of Remington's Pharmaceutical Sciences (Maa
ck Publishing, Easton PA). Such a composition is
S, an antibody of HTFS, a mimetic, an agonist, an antagonist, an inhibitor of HTFS, or the like.

The compositions used in the present invention can be administered by a variety of routes. This route includes oral, intravenous, intramuscular, intraarterial, intramedullary, subarachnoid, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal. Are not limited to these.

Compositions for pulmonary administration can be prepared in liquid or dry powder form. Such compositions are typically aerosolized shortly before inhalation by the patient. Small molecules (eg,
For conventional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well known in the art. In the case of macromolecules (for example, larger peptides and proteins), the technology of pulmonary transport via the alveolar region of the lung has improved in recent years, and it has become possible to actually transport drugs such as insulin into the blood ( Patton, JS et al., US Patent No. 5,997,848
See No.). Pulmonary transport is superior in that it can be administered without needle injection, obviating the need for potentially toxic penetration enhancers.

Suitable compositions for use in the present invention include compositions which contain an effective amount of the active ingredient to achieve the object. Those of ordinary skill in the art are well able to determine an effective dose with their own ability.

The particular shape of the composition is prepared to deliver macromolecules, including HTFS or fragments thereof, directly into cells. For example, liposomal formulations containing cell-impermeable macromolecules can facilitate cell fusion and intracellular transport of macromolecules. Alternatively, use HTFS or its fragments
It can also bind to the cationic N-terminal part of the HIV Tat-1 protein. It has been confirmed that the fusion protein thus produced is transduced into cells of all tissues including the brain of a mouse model system (Schwarze, SR et al. (1999) Science 285).
: 1569-1572).

For any composition, the therapeutically effective dose can be estimated initially either in tumor cell assays, eg, of tumor cells, or in animal models. Usually, mouse, rabbit, dog, monkey, pig or the like is used as the animal model. Animal models can also be used to determine the appropriate concentration range and route of administration. Based on such treatment, a beneficial dose and administration route for human can be determined.

A medically effective dose is related to the amount of active ingredients, such as HTFS or fragments thereof, antibodies of HTFS, agonists or antagonists of HTFS, inhibitors, etc. that ameliorate symptoms or conditions. Medicinal efficacy and toxicity are calculated by, for example, ED ₅₀ (dose that is medicinally effective in 50% of the population for taking) or LD ₅₀ (dose that is fatal in 50% of the population for taking) statistics. Can be determined by standard drug techniques in cell culture or animal studies. Dosage ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as LD _{50 /} ED _50. Compositions that exhibit high therapeutic indices are desirable. The data obtained from cell culture assays and animal studies are used in formulating a range of dosage for human applications. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED ₅₀ with little or no toxicity. The dosage will vary within this range depending upon the dosage form employed, the patient sensitivity, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the patient that requires treatment. Dosage and administration are adjusted to provide effective levels of the active ingredient or to maintain the desired effect. Dosage factors considered include disease severity, general health of the patient, age, weight, and sex of the patient, time and frequency of administration, concomitant medications, response susceptibility, and treatment. Contains the response. Long-acting compositions may be administered once every three or four days, once a week, once every two weeks, depending on the half-life and clearance rate of the particular formulation.

[0187] The usual dosage varies depending on the route of administration, but is up to about 1 gram up to about 0.1 to 100,000 μg. Guidance on specific dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. One of skill in the art will utilize formulations of nucleotides that are different than the protein or inhibitor. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

Diagnosis In another example, a patient who is diagnosed with a disease in which an antibody that specifically binds to HTFS is characterized by the expression of HTFS or is treated with HTFS or an agonist or antagonist of HTFS, an inhibitor. Used in an assay to monitor Antibodies useful for diagnosis are formulated in the same manner as described in treatment.
HTFS diagnostic assays include methods of detecting HTFS from human body fluids or from cells and tissues using antibodies and labels. These antibodies, used with or without modification, can be labeled by covalent or non-covalent attachment of reporter molecules. Various reporter molecules known in the art are used, some of which have been mentioned above.

Various protocols, including ELISA, RIA, and FACS for measuring HTFS are well known in the art and provide a basis for diagnosing altered or abnormal levels of HTFS expression. The value of expression of normal or standard HTFS is determined by binding an antibody against HTFS to a body fluid or cell collected from a subject such as a normal mammal, for example, a human under conditions suitable for complex formation. To do. The amount of canonical complex formation can be quantified by various methods such as photometric. Amounts of HTFS expression, control and disease in the subject, samples from biopsy tissue are compared to baseline. The deviation between the reference value and the subject is an index for diagnosis.

According to another embodiment, the polynucleotide encoding HTFS can also be used for diagnosis. The polynucleotide used includes an oligonucleotide sequence,
Included are complementary RNA and DNA molecules, and PNAs. This polynucleotide is used to detect and quantify the expression of genes in biopsied tissues that express HTFS that can be correlated with disease. Use this diagnostic assay to check for the presence or absence of HTFS and for overexpression,
Monitor regulation of HTFS levels during treatment.

In certain embodiments, it is possible to identify a nucleic acid sequence encoding HTFS by hybridization with a PCR probe capable of detecting a polynucleotide sequence comprising a gene sequence encoding HTFS or a closely related molecule. is there. The specificity of the probe, whether it is made from a highly specific region, for example the 5'regulatory region, or a region with less specificity, which is a conserved motif, and the stringency of hybridization or amplification, Will identify only the natural sequence that encodes HTFS, or will only identify the natural sequence that encodes the allele or related sequence.

Probes may also be utilized in the detection of related sequences and may have at least 50% sequence identity with any sequence encoding HTFS. The desired hybridization probe of the present invention can be DNA or RNA and can be derived from the sequence of SEQ ID NO: 43-84 or the genomic sequence of the HTFS gene including promoter, enhancer and intron.

As a method for producing a hybridization probe specific for HTFS-encoding DNA, there is a method of cloning a polynucleotide sequence encoding HTFS and an HTFS derivative into a vector for producing an mRNA probe. Such vectors are commercially available, well known to those skilled in the art, and are used to synthesize RNA probes in vitro by adding a suitable RNA polymerase and a suitable labeled nucleotide. Hybridization probes can be labeled with a population of different reporters such as radionuclides such as ³² P or ³⁵ S, or enzyme labels such as alkaline phosphatase linked to the probe by an avidin / biotin binding system.

Polynucleotide sequences encoding HTFS can be used to diagnose diseases associated with the expression of HTFS. Without limitation, such diseases include:
Abnormal cell proliferation and diseases of the immune system are included. Among the abnormal cell proliferation are actinic keratoses and atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD),
Myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and adenocarcinoma and leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma, specifically the adrenal gland. , Bladder, bone, bone marrow, brain, breast, cervix, gallbladder, ganglion, digestive tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid gland, penis, prostate, salivary gland, skin, testis, thymus, It includes cancers of the thyroid and uterus, among which diseases of the immune system include inflammation and actinic keratoses, acquired immunodeficiency syndrome (AIDS) and adrenal insufficiency, adult respiratory distress syndrome, allergies, ankylosing spine. Inflammation, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, contact dermatitis, Crohn's disease, Atopic dermatitis, dermatomyositis, diabetes, emphysema , Erythroblastosis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable colon Syndrome, lymphotoxin-induced transient lymphopenia, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis , Pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, platelets Includes reduced purpura, ulcerative colitis, uveitis, Werner syndrome, cancer complications, hemodialysis, extracorporeal circulation, trauma, and hematopoietic cancers including lymphoma, leukemia, myeloma. The HTFS-encoding polynucleotide sequence can be expressed by Southern, Northern, dot-blot, or other membrane-based techniques, PCR, dipstick, pin, ELISA assay, and expression of mutant HTFS. Can be used in a microarray that utilizes body fluids or tissues collected from a patient to detect Such qualitative or quantitative methods are well known in the art.

In one embodiment, the nucleotide sequences encoding HTFS will be useful in assays to detect related disorders, particularly the disorders mentioned above. The nucleotide sequence encoding HTFS may be labeled by standard methods and added to a body fluid or tissue sample taken from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the samples are washed and the signal is quantified and compared to the reference value. If the amount of signal in the patient sample is significantly altered compared to the control sample, the level of mutation of the nucleotide sequence encoding HTFS in the sample reveals the presence of the associated disease. Such assays can be used to estimate the effectiveness of a particular treatment in animal studies, clinical trials, or monitoring individual patient treatment.

A normal or canonical expression profile is established to provide a basis for diagnosis of diseases associated with expression of HTFS. This can be achieved by combining the HTFS coding sequence or a fragment thereof with a body fluid or cell extracted from a normal subject, either animal or human, under conditions suitable for hybridization or amplification. . Standard hybridizations can be quantitated by comparing the values obtained from normal subjects to those from experiments in which known amounts of substantially purified polynucleotides are used. Standard values obtained from normal samples can be compared with those obtained from subjects who exhibit symptoms of the disease. The deviation between the reference value and the subject's value is used to determine whether or not the patient is affected.

Once the presence of the disease has been established and the treatment protocol has begun, the hybridization assay is repeated on a regular basis to estimate whether the level of expression in the subject has begun to approach the values shown in normal patients. Is possible. The results of repeated assays can be used to see the effect of treatment over a period of days to months.

In cancer, abnormal amounts of transcripts in living tissue from an individual predispose to the development of the disease and can provide a method of detecting the disease before actual clinical symptoms develop. is there. This type of clearer diagnosis allows medical professionals to use preventative or aggressive therapies early to prevent the development or progression of cancer.

Further diagnostic uses of oligonucleotides designed from sequences encoding HTFS can include the use of PCR. Such oligomers are chemically synthesized,
It can be produced enzymatically or in vitro . The oligomer is preferably
It contains a fragment of a polynucleotide encoding HTFS or a fragment of a polynucleotide complementary to the polynucleotide encoding HTFS, and is used to identify a specific gene or condition under the optimum conditions. Further, the oligomer can be used for detecting and / or quantifying a closely related DNA or RNA sequence under slightly mild stringent conditions.

In certain embodiments, oligonucleotide primers derived from a polynucleotide sequence encoding HTFS can be used to detect single nucleotide polymorphisms (SNPs). SNPs are nucleotide substitutions, insertions and deletions that often cause congenital or acquired genetic disorders in humans. Methods of detection of SNPs include, but are not limited to, single-stranded conformational polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, DNA is amplified by polymerase chain reaction (PCR) using an oligonucleotide primer derived from a polynucleotide sequence encoding HTFS. This DNA can be derived, for example, from lesions or normal tissue, biopsy samples, body fluids and the like. The SNPs in this DNA are single-stranded
It makes a difference in the secondary and tertiary structure of the PCR product. This difference can be detected using gel electrophoresis in a non-denaturing gel. In fSCCP, by fluorescently labeling an oligonucleotide primer, it becomes possible to detect an amplimer with a high throughput device such as a DNA sequencing device. In addition, a sequence database analysis method called in silico SNP (isSNP) can identify polymorphisms by comparing the sequences of individual overlapping DNA fragments used to construct a common consensus sequence. . These computer-based methods eliminate sequence variability due to automated analysis of DNA sequence chromatograms and sequencing errors using statistical models and DNA adjustments in the laboratory. Alternatively, for example, the high throughput MASSARRAY system (Sequenom, Inc.
, San Diego CA) to detect and characterize SNPs by mass spectrometry.

Methods that can be used to quantify the expression of HTFS include radiolabelling or biotin labeling of nucleotides, coamplification of regulatory nucleic acids, and standard curves with the results added. (For example, Melby, PC et al. (1993) J. Imm
unol. Methods, 159: 235-44; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The quantitation rate of a large number of samples was accelerated by using a high-throughput assay in which the oligomer or polynucleotide of interest was included in various dilutions and the quantitation was rapid by spectrophotometry or non-color response.

In yet another example, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein can be used as targets in microarrays. Microarrays can be used in transcription imaging techniques to simultaneously monitor the relative expression levels of multiple genes. In this regard, U.S. Pat. No. 5,840,484 issued to Seilhamer, JJ et al.
Native Gene Transcript Analysis ”), which is incorporated herein by reference. Microarrays can also be used to identify genetic mutations, mutations and polymorphisms. This information can be used to determine gene function, elucidate the genetic basis of the disease, diagnose the disease, monitor the progression / regression of diseases associated with gene expression, and develop and activate therapeutic agents in the treatment of disease. Can be monitored. In particular, this information can be used to develop a pharmacogenomic profile of a patient in order to select the optimal and effective treatment regimen for the patient. For example, based on a patient's pharmacogenomic profile, therapeutic agents can be selected that are highly effective but have few side effects on the patient.

In another example, antibodies specific for HTFS, HTFS or fragments thereof can be used as elements on the microarray. Microarrays can be used to monitor and measure protein-protein interactions, drug-target interactions and gene expression profiles as described above.

Certain examples relate to the use of the polynucleotides of the invention to produce a transcriptional image of a tissue or cell type. Transcriptional images represent global patterns of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number and relative abundance of genes expressed at a given time under a given condition (Seilliamer et al., US Patent No. 5,840,484, "Comparative Gene Transc").
ript analysis ", which is hereby incorporated by reference for this patent), and thus the entire transcript or reverse transcript of a particular tissue or cell type is A hybrid image can be generated by hybridizing its complementary sequences, hi one embodiment, the polynucleotides of the invention or their complementary sequences hybridize in a high-throughput fashion to form a subset of multiple elements on a microarray. The resulting transcriptional image can be a profile of gene activity.

Transcript images can be generated using transcripts isolated from tissues, cell lines, biopsy samples, or other biological samples. Thus, the transcriptional image reflects gene expression in vivo for tissue or biopsy samples, or in vitro for cell lines.

Transcriptional images showing the expression profile of the polynucleotides of the invention can also be used in connection with in vitro model systems and preclinical evaluation of drugs, as well as toxicity studies of synthetic or natural compounds. All compounds cause characteristic gene expression patterns, often referred to as molecular fingerprints or toxicity signatures, that suggest mechanisms of action and toxicity (Nuwaysir, EF et al. (1999) Mol.
Carcinog. 24:15 3-159, Steiner, S. and NL Anderson (2000) Toxicol. Let
t. 112-113: 467-471, and also incorporated herein by reference). A test compound is likely to share toxic properties if it has the same signature as the signature of a known compound with toxicity. The more useful and accurate the fingerprint or signature contains expression information from more genes and gene families. Ideally, the expression should be measured across the genome and provide the highest quality signature. Similarly important are genes whose expression is not altered by any test compound. It is because the expression levels of these genes can be used to normalize the rest of the expression data. Normalized treatment is useful for comparing expression data after treatment with different compounds. Although assigning gene function to elements of a toxicity signature helps to elucidate the mechanism of toxicity, statistical knowledge of signatures leading to toxicity prediction requires no knowledge of gene function (eg, February 29, 2000). National Institute of Environmenta
See Press Release 00-02 published by Health Sciences. This is available at http://www.niehs.nih.gov/oc/news/toxchip.htm).
Therefore, it is important and desirable to include all expressed gene sequences in toxicity screens using the toxicity signature.

In one example, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acid with the test compound. The nucleic acid expressed in the treated biological sample can be hybridized with one or more probes specific for the polynucleotide of the invention, thereby quantifying the transcription level corresponding to the polynucleotide of the invention. The transcription level in the treated biological sample is compared to the level in the untreated biological sample. The difference in the transcription level of both samples is indicative of the toxic reaction that the test compound causes in the treated samples.

Another example relates to analyzing the proteome of a tissue or cell type using the polypeptide sequences of the invention. The term "proteome" refers to the global pattern of protein expression in a particular tissue or cell type. Each protein that makes up the proteome can be further analyzed individually. The proteome expression pattern or profile is analyzed by quantifying the number of proteins expressed under a given condition at a given time and their relative abundance. Therefore,
A proteomic profile of a cell can be generated by isolating and analyzing polypeptides of a particular tissue or cell type. In some embodiments, such separation is performed by two-dimensional gel electrophoresis. In this two-dimensional gel electrophoresis method, first,
Proteins are separated from the sample by one-dimensional isoelectric focusing and then by molecular weight by two-dimensional sodium dodecyl sulfate slab gel electrophoresis (
Steiner and Anderson). These proteins are visualized in the gel as spots in discrete discrete locations, usually by staining the gel with stains such as Coomassie blue or silver or fluorescent stains. The optical density of each protein spot is usually proportional to the protein level in the sample. The optical densities of co-located protein spots obtained from different samples, eg, biological samples, either treated or untreated with a test compound or therapeutic agent, are compared to determine changes in protein spot density associated with treatment. The proteins in the spot are
For example, chemical or enzymatic cleavage followed by partial sequencing using standard methods of mass spectrometry. The identity of a protein within a spot can be determined by comparing its partial sequence, which is preferably at least 5 consecutive amino acid residues, to a polypeptide sequence of the invention. In some cases, additional sequences for definitive protein identification are obtained.

Proteome profiles can also be generated by quantifying HTFS expression levels using antibodies specific for HTFS. In one example, protein expression levels are quantified by using antibodies as elements on the microarray and exposing the microarray to a sample to detect the level of protein binding to each array element (Lueking, A. et al. (1999). ) Anal. Biochern. 270: 103-111, Mendoz
e, LG et al. (1999) Biotechniques 27: 778-788). Detection can be accomplished by a variety of methods known in the art, for example, thiol-reactive or amino-reactive fluorescent compounds can be used to react proteins in a sample to detect the amount of fluorescent binding at each array element. .

The toxicity signature at the proteome level is also useful for toxicological screening and should be analyzed in parallel with the toxicity signature at the transcription level. For some proteins in some tissues, the abundance of transcripts and protein abundance may be low (Anderson, NL and J. Seilhamer (1997) Electrophores
18: 533-537), the proteome toxicity signature may be useful in the analysis of compounds that do not significantly affect the transcriptional image but alter the proteome profile. Furthermore, analysis of transcription in body fluids is difficult due to the rapid degradation of mRNA. Therefore, proteome profiling in such cases is more reliable and informative.

In another example, the toxicity of a test compound is assessed by treating a biological sample containing the protein with the test compound. The proteins expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the corresponding amount of protein in the untreated biological sample. Differences in the amount of protein in both samples indicate a toxic response to the test compound in the treated samples. Individual proteins sequence their amino acid residues,
These partial sequences are identified by comparison with the polypeptide of the invention.

In another example, the toxicity of a test compound is assessed by treating a biological sample containing the protein with the test compound. Proteins obtained from biological samples are incubated with antibodies specific for the polypeptides of the invention. The amount of protein recognized by the antibody is quantified. The amount of protein in the treated biological sample is compared to the amount of protein in the untreated biological sample. The difference in the amount of protein in both samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays are prepared, used, and analyzed by methods well known in the art. (For example, Brennan, TM et al. (1995) US Pat. No. 5,474,796; Schena, M. et al. (1996) Pro.
c. Natl. Acad. Sci. 93: 10614-10619; Baldeschweiler et al. (1995) PCT application number W
O95 / 251116; Shalon, D. et al. (1995) PCT application number WO95 / 35505; Heller, RA et al. (1
997) Proc. Natl. Acad. Sci. 94: 2150-2155; and Heller, MJ et al. (1997) U.S. Pat. No. 5,605,662). Various types of microarrays are well known and for details see DNA Microarrays: A Practical Approach , M. Schena, ed.
9) Described in Oxford University Press, London. In addition, this document is incorporated by reference.

In another embodiment of the invention, the nucleic acid sequences encoding HTFS can also be used to generate hybridization probes that are useful in mapping native genomic sequences. Either coding or non-coding sequences can be used, but in some cases non-coding sequences are preferred over coding sequences. For example, conserved coding sequences between members of a multigene family can result in unwanted cross-hybridization during chromosome mapping. This sequence can be a specific chromosome, a specific region of a chromosome or an artificial chromosome, such as a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), a bacterial artificial chromosome (BAC), a bacterial P1 product, or a single chromosome cDNA library. (Harrington, JJ et al. (1997) Nat Genet. 15: 345-355, Pric.
e, CM (1993) Blood Rev. 7: 127-134, Trask, BJ (1991) Trends Genet. 7:
See 149-154 etc.). Once mapped, the nucleic acid sequences of the invention can be used, for example, to create a gene linkage map that correlates the inheritance of a disease state with a particular chromosomal region or restriction fragment length polymorphism (RFLP) inheritance (Lander). , ES and D. Botstein
(1986) Proc. Natl. Acad. Sci. USA 83: 7353-7357).

In situ fluorescence hybridization (FISH) can be correlated with other physical and genetic map data (eg, Heinz-Ulrich, et al. (1995) in Meyers, supra).
, pp. 965-968). Examples of genetic map data can be found in various scientific journals or Onlin
It can be found on the World Wide Web site of e Mendelian Inheritance in Man (OMIM). Correlation between the position of the gene encoding HTFS on the physical chromosomal map and a specific disease, or a predisposition to a specific disease, helps determine the DNA region associated with such a disease, so additional positions are required. The cloning to determine is performed.

The genetic map can also be extended using physical mapping techniques such as in sit hybridization of chromosomal preparations and binding analysis using established chromosomal markers. Placing a gene on the chromosome of another mammal, such as a mouse, often reveals related markers, even if the precise human chromosome location is not known. This information is valuable to researchers investigating genetic disorders using positional cloning or other gene discovery techniques. The location of one or more genes involved in the disease or syndrome is
When roughly determined by gene binding to a specific gene region such as 11q22-23,
Any sequence mapping to that region represents a relevant or regulatory gene for further investigation (eg Gatti, RA et al. (1988) Nature 336: 57.
See 7-580). In addition, the target nucleotide sequence of the present invention may be used to detect a difference in chromosomal position between a normal subject and a carrier, that is, an infected subject due to translocation, inversion, or the like.

In another embodiment of the invention, HTFS, its catalytic or immunogenic fragments or oligopeptides thereof can be used to screen a library of compounds in any of a variety of drug screening techniques. Fragments used for such screening may be free in solution, immobilized on a solid support, retained on the surface of cells, or present intracellularly. Complex formation due to binding of HTFS to the agent being tested may be measured.

Another method used for drug screening is used to increase the screening throughput of compounds with suitable binding affinity for the protein of interest (eg, Geysen, et al. (1984) PCT Application No. See WO84 / 03564). In this method, a significant number of different small test compounds are synthesized on plastic pins or other substrates. The test compound is reacted with HTFS, or a fragment thereof, and then washed. The bound HTFS is then detected by methods well known in the art. Purified HTFS can also be coated directly on plates used in the drug screening techniques described above. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another example, a competitive drug screening assay may be used in which neutralizing antibodies capable of binding HTFS specifically compete with the test compound for binding to HTFS.
In this method, the antibody detects the presence of any peptide that shares one or more antigenic determinants with HTFS.

In another example, nucleotide sequences encoding HTFS are used in evolving molecular biology techniques, including, but not limited to, currently known nucleotides such as the triplet code and specific base pair interactions. New technologies can be provided that depend on the characteristics of the sequence.

Those skilled in the art will be able to maximize the use of the present invention without further explanation given the preceding description. Therefore, the specific preferred embodiments described below are for purposes of illustration and not limitation of the present invention.

All patent applications, patents, publications mentioned above and below, especially US patent application Ser. No. 60 / 163,595, are hereby incorporated by reference.

Example 1 Preparation of cDNA Library RNA was purchased from Clontech, or isolated from the tissues listed in Table 4. First, while homogenizing a part of this tissue and dissolving it in a guanidinium isothiocyanate solution, homogenizing another part of this tissue and dissolving it in phenol, or TRIZOL (Life Technologies), guanidinium Dissolved in a mixture of suitable modifiers such as a single phase solution of thiocyanate and phenol. The lysate was extracted by centrifugation over cesium chloride or with chloroform. RNA was precipitated from this lysate with either isopropanol or sodium acetate and ethanol, or otherwise.

RNA extraction with phenol and precipitation were repeated as many times as necessary to increase the purity of the RNA. In some cases, RNA is treated with a DNA degrading enzyme. Most libraries have oligo d (T) -linked paramagnetic particles (Promega) or OLIGOTEX latex particles (QIAGEN).
Valencia CA), OLIGOTEX mRNA purification kit (QIAGEN) was used to isolate poly (A +) RNA. Alternatively, it was isolated directly from tissue lysates using another RNA isolation kit such as the POLY (A) PURE mRNA purification kit (Ambion, Austin TX).

[0225] In some cases, RNA was provided to Stratagene and a cDNA library corresponding to Stratagene was created. Otherwise, UNIZAP vector system (Stratagene)
Alternatively, a cDNA library was prepared by using the SUPERSCRIPT plasmid system (Life Technologies) to synthesize cDNA by a recommended method known in the art or a similar method.
(See, eg, Ausubel, 1997, supra, Units 5.1-6.6). Reverse transcription is oligo d (T)
Or started with random primers. A synthetic oligonucleotide adapter was attached to the double-stranded cDNA and the cDNA was digested with a suitable restriction enzyme or restriction enzymes. For most libraries, SEPHACRYL S 1000 or SEPHAROSE
CL2B, SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech
), And the size of the cDNA (300-1000 bp) was selected by agarose gel electrophoresis. PBLUESCRIPT plasmid (Stratagene) or pSPORT1 plasmid (Life Technolo
gies), pcDNA2.1 plasmid (Invitrogen Carlsbad CA), plNCY plasmid (Incyt
The cDNA was attached to the compatible restriction enzyme sites of the polylinker of a suitable plasmid such as ePharmaceuticals, Palo Alto CA). Use this recombinant plasmid with Stratagene XL1-Blue, XL1-BIueMRF, SOLR, or Life Technologies DH5α or DH.
10B, ELECTROMAX DH 10B was introduced into competent E. coli cells and incorporated.

2 Isolation of cDNA clones The plasmids obtained as described in Example 1 above were UNIZAP vector system (S
tratagene) or by in vivo excision using cell lysis. Magic or WIZARD Minipreps DNA Purification System (Promega), and AGTC Minip
rep purification kit (Edge Biosystems, Gaithersburg MD), QIAGEN's QIAWELL 8 Pla
smid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid Purification System, REAL
Plasmids were purified using at least one of the Prep 96 plasmid kits. After precipitation, it was resuspended in 0.1 ml of distilled water and stored at 4 ° C. with or without freeze-drying.

Alternatively, plasmid DNA was amplified from host cell lysates by a high throughput direct ligation PCR method. (Rao, VB (1994) Anal. Biochem. 216: 1-14). Host cell lysis and thermal cycling processes were performed in a single reaction mixture. Samples are processed and transferred to 384-well plates for storage and the concentration of amplified plasmid DNA is quantified using PICOGREEN dye (Molecular Probes, Eugene OR) and Fluoroskan II fluorescence scanner (Labsystems Oy, Helsinki, Finland). Measured.

3 Sequencing and Analysis The Incyte cDNA recovered in the plasmid as described in Example 2 was:
Sequenced as shown below. The cDNA sequencing reaction can be performed using standard methods or ABI CATALYST 800 (PE Biosystems) thermal cycler or P
TC-200 thermal cycler (MJ Research) and HYDRA micro dispenser (Robbins
Scientific) or MICROLAB 2200 (Hamilton) liquid transfer system in combination with a high throughput instrument. To prepare the cDNA sequencing reaction, use Amersham Pharmacia Biotech's reagent or ABI PRISM BIGDYE Terminato.
The reagents included in the ABI sequencing kit such as r cycle sequencing ready reaction kit (PE Biosystems) were used. MEGABACE 1000 DNA Sequencing System (Molecular Dynamics), ABI PRISM 373 or 377 Sequencing System using base pair calling software for electrophoretic separation of labeled cDNA sequencing reactions and detection of labeled polynucleotides.
(PE Biosystems), other sequence analysis systems well known in the art were used. The open reading frame of the cDNA sequence was determined using standard methods (Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected and extended by the method described in 6 of this Example.

The construction and analysis of the polynucleotide sequences obtained from the sequencing of the cDNA was performed in combination with software utilizing algorithms well known to those skilled in the art.
Table 5 outlines the tools, software, algorithms utilized, their description, references, and threshold parameters used. Column 1 of Table 5 is the tools and programs used, algorithms, column 2 is a brief description thereof, column 3 is a reference cited as part of this specification by reference, column 4 is a sequence of two sequences. The score, probability value, and other parameters used in the evaluation of the degree of coincidence are shown (the higher the probability value, the higher the homology between sequences). MACDNASIS PRO software (Hitachi Softwa
re Engineering, S. San Francisco CA) and LASER GENE software (DNASTAR)
Was used.

Confirmation of the polynucleotide sequence is performed by using BLAST and dynamic programming, programs and algorithms based on dinucleotide nearest neighbor analysis to remove vectors and linkers, poly A sequences and mask ambiguous base pairs. I went there. next,
Using databases based on BLAST, FASTA and BLIMPS, public databases such as GenBank primates and rodents, mammals, vertebrates, eukaryotic databases and BLOCKS, PRINTS, DOMO, PRODOM and PFAM databases. Annotations were obtained by querying these sequences against sequences selected from. These sequences were constructed into full-length polynucleotide sequences using programs based on Phred and Phrap, Consed and screened for open reading frames with programs based on BLAST and FASTA, BLIMPS. The full-length polynucleotide sequence is translated to derive the corresponding full-length amino acid sequence, and the GenBank database (above) and databases such as SwissProt, BLOCKS, PRINTS, DOMO, PRODOM and Prosite,
Alternatively, these full-length sequences were analyzed by querying a protein family database based on Hidden Markov Models (HMM) such as PFAM. HMMs use probabilities to analyze consensus primary structure of gene families (eg, Ed
dy, SR (1996) Curr. Opin. Struct. Biol. 6: 361-365).

The programs described above for the construction and analysis of full length polynucleotide and amino acid sequences can also be used to identify fragments of the polynucleotide sequence from SEQ ID NO: 43-84. Fragments of up to about 20-4000 nucleotides are useful for hybridization and amplification and have been described in the invention above.

4 Analysis of Polynucleotide Expression Northern analysis is an experimental technique used to detect the presence of transcripts of a gene, labeling the membrane bound RNA from a particular cell type or tissue. (See, eg, Sambrook, supra,
Chapter 7; and Ausubel. FM et al., Supra, Chapters 4 and 16).

Using similar computer technology for BLAST, GenBank or LIFESEQ (Inc
Search for identical or related molecules in cDNA databases such as yte Pharmaceuticals). This assay is much faster than many membrane-based hybridizations. In addition, the sensitivity of computer searches can be modified to determine whether any particular match is classified as an exact or homologous match. Search criteria are

[0234]

[Equation 1]

Is the product score defined as The product score is a standardized value of 0-100 and is calculated as follows. Multiply the BLAST score by the percent identity of the nucleotide sequences,
The product is divided by 5 times the shorter length of the two sequences. The BLAST score is calculated by assigning a score of +5 to each base that matches in the high scoring segment pair (HSP) and a score of -4 to each mismatch. The two sequences may share more than one HSP (separated by a gap). If there are two or more HSPs, the product score is calculated using the base pair with the highest BLAST score. The product score represents the balance between fragmental overlap and quality of BLAST alignments. For example, the product score 100 is
Only obtained if there is 100% match over the shorter length of the two sequences compared. The product score 70 is either 100% coincidence and 70% overlap at one end, or 88% coincidence and 100% overlap at the other end. The product score 50 is either 100% coincidence and 50% overlap at one end, or 79% coincidence and 100% overlap at the other end.

Results of Northern analysis are reported as the percent distribution of the library in which transcripts encoding HTFS occurred. The analysis also includes classification of the cDNA library by organ / tissue and disease. Organ / tissue categories include cardiovascular, skin, development, endocrine,
Includes gastrointestinal, hematopoietic / immune, musculoskeletal, neural, reproductive, urological. Disease categories include cancer, inflammation, trauma, cell proliferation, nerves, pooled. By category, the number of libraries expressing the sequence of interest was counted and divided by the number of libraries in the entire range. Table 3 shows the ratio (percentage) of specific expression in each tissue and the ratio of expression in each disease.

Chromosomal Mapping of a Polynucleotide Encoding 5 HTFS The cDNA sequence used to construct SEQ ID NO: 43-84 was prepared using BLAST and Smith-Waterm.
The an algorithm was used to compare sequences from the Insight LIFESEQ database and public domain databases. Sequences from these databases that matched SEQ ID NO: 43-84 were assembled into a cluster of contiguous and overlapping sequences using a construction algorithm such as Phrap (Table 5). Stanford Human Genonse Center (SHG
C), Whitehead Institute for Genome Research (WIGR) and radiation hybrid and gene mapping data available from public sources such as Genethon will be used to determine if the clustered sequences have already been mapped. If the cluster contained mapped sequences, all sequences of that cluster (including the particular SEQ ID NO) were assigned to that mapping position.

SEQ ID NO: 44, 46, 48, 49, 52, 59, 60, 62, 68, 78, 85, and SEQ ID NO: 86
The location of the genetic map of is described in the invention section herein as an interval or range of the human chromosome. More than one genetic map location reported for SEQ ID NO: 59, 78, 85, and SEQ ID NO: 86 means that SEQ ID NO: 59, 78, 85, and SEQ ID N:
It suggests that previously mapped sequences with similarities to O: 86 but not completely identical were incorporated into their respective clusters. The range of mapping positions shown in centimorgan is measured from the end of the short arm (p) of the chromosome (centimorgan (cM) is a unit indicating the distance based on the crossover rate between genes on the same chromosome. On average, 1 cM is roughly equivalent to 1 megabase of human chromosomes,
There may be a high recombination rate and a low recombination rate, which may cause major changes). The distance cM is based on the genetic markers mapped by Genethon that can detect the boundaries of the radiation hybrid markers whose sequences are contained in each cluster.
For example, NCBI "GeneMap'99" World Wide Web site (http: J / www.ncbi.nlm.nih.
A publicly available human genome map (e.g. sJovfenemap /) and other information can be used to determine whether to map the previously identified lesion genes within or around the above range.

6 Extension of a Polynucleotide Encoding HTFS The full-length nucleic acid sequence of SEQ ID NO: 43-84 was prepared using oligonucleotide primers designed from suitable fragments of the full-length molecule. The fragment was extended and produced. One primer was synthesized to initiate the 5'extension of the known fragment and the other primer was synthesized to initiate the 3'extension of the known fragment. Starting primers were about 5 to about 5 nucleotides in length from about 22 to about 30 using OLIGO 4.06 software (National Biosciences) or other suitable program.
It had a GC content of 0% or higher and was designed to anneal to the target sequence at a temperature of about 68-72 ° C. Nucleotides were extended so that hairpin structures and primer-primer dimers did not occur.

This sequence was extended with selected human cDNA libraries. If more than one extension is required or desired, additional or nested primer sets are designed.

Amplification was performed with high fidelity by the PCR method using a method known in the art. PCR is PTC-200
It was performed in a 96-well block plate using a thermal cycler (MJ Research, Inc.). The reaction mixture consisted of template DNA, 200 nmol of each primer, Mg ²⁺ and (NH ₄ ) ₂ SO ₄ and β.
− Buffer containing mercaptoethanol, Taq DNA polymerase (Amersham Pha
rmacia Biotech), ELONGASE enzyme (Life Technologies), Pfu DNA polymerase (St
ratagene). Amplification was performed on the primer set, PCI A and PCI B, with the following parameters. Step 1 94 ° C. for 3 minutes Step 2 94 ° C. for 15 seconds Step 3 60 ° C. for 1 minute Step 4 68 ° C. for 2 minutes Step 5 Repeat steps 2, 3, and 4 20 times Step 6 68 ° C. for 5 minutes Step 7 Storage at 4 ° C Alternatively, amplification was performed on the primer set, T7 and SK +, with the following parameters. Step 1 94 ° C. for 3 minutes Step 2 94 ° C. for 15 seconds Step 3 57 ° C. for 1 minute Step 4 68 ° C. for 2 minutes Step 5 Repeat steps 2, 3, and 4 20 times Step 6 68 ° C. for 5 minutes Step 7 Store at 4 ° C.

The DNA concentration in each well was dissolved in 1X TE and 0.5 μl of undiluted PCR product.
100 μl PICOGREEN quantification reagent (0.25% (v / v) PICOGREEN; Molecular Probes, Eugen
e OR) is distributed to each well of an opaque fluorometer plate (Coming Costar, Acton MA) to allow the DNA to bind to the reagent and be measured. Fluoroskan this plate
Scan with II (Labsystems Oy, Helsinki, Finland) and measure the fluorescence of the sample to quantify the concentration of DNA. A 5-10 μl aliquot of the reaction mixture is analyzed by electrophoresis on a 1% agarose minigel to determine which reaction succeeded in extending the sequence.

The extended nucleotides are desalted and concentrated before being transferred to a 384 well plate, Cvi
JI Cholera virus endonuclease (Molecular Biology Research, Madison W
Digested with I) and sonicated or sheared before religation to pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on a low concentration (0.6-0.8%) agarose gel to cut the fragments and the agar was digested with Agar ACE (Promega). T4 Ligase (New England B
The clones extended with iolabs, Beverly MA) were cloned into pUC 18 vector (Amersham Pha
rmacia Biotech) and treated with Pfu DNA polymerase (Stratagene) for restriction site extension to transfect competent E. coli cells. The transfected cells were selected and transferred to a medium containing antibiotics, each colony was cut off, and cultured in a 384-well plate of LB / 2X carbenicillin culture solution at 37 ° C. overnight.

Cells were lysed and Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu
DNA was PCR amplified using DNA polymerase (Stratagene) according to the following procedure. Step 1 94 ° C. for 3 minutes Step 2 94 ° C. for 15 seconds Step 3 60 ° C. for 1 minute Step 4 72 ° C. for 2 minutes Step 5 Repeat Steps 2, 3 and 4 29 times Step 6 72 ° C. for 5 minutes Step 7 Store at 4 ° C. DNA was quantified with PICOGREEN reagent (Molecular Probes) as described above. Samples with poor DNA recovery were amplified again under the above conditions. Samples were diluted with 20% dimethysulphoxide (1: 2, v / v) and used in the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or ABI PRISM BIGDYE Terminator cycle se.
Sequencing was performed using the quencing ready reaction kit (PE Biosystems).

Similarly, following the procedure described above, utilizing the nucleotide sequence of SEQ ID NO: 43-84, 5'with the oligonucleotide designed for this extension and a suitable genomic library.
The regulatory sequence was obtained.

7 Labeling and Use of Individual Hybridization Probes Hybridization probes derived from SEQ ID NO: 43-84 are used to screen cDNA, mRNA, or genomic DNA. Special mention is made of labeling of oligonucleotides of about 20 base pairs, but essentially the same procedure is used for larger cDNA fragments. Oligonucleotides were designed using state-of-the-art software, such as OLIGO 4.06 software (National Bioscience), with 50 pmol of each oligomer and 250 μCi [γ- ³² P] adenosine triphosphate (A
mersham, Chicago, IL) and T4 polynucleotide kinase (DuPont NEN, Bost)
on MA) and used in combination for labeling. The labeled oligonucleotide was loaded onto a SEPHADEX G-25 ultrafine exclusion dextran bead column (Amersham Phar
Substantially purified using macia Biotech). An aliquot containing the labeled probe at 10 ⁷ counts per minute was added to the following endonucleases: Ase I, Bgl II, Eco R.
Human genome cleaved with one of I, Pst I, Xba1 or Pvu II (DuPont NEN)
Used in typical membrane-based hybridization analysis of DNA.

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to a nylon membrane (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is performed at 40 ° C. for 16 hours. To remove non-specific signals, the blots are sequentially washed at room temperature, eg, under conditions of max 0.1 × sodium citrate saline and 0.5% sodium dodecyl sulfate. The hybridization patterns are visualized and compared by autoradiography or another imaging means.

8 Microarrays Linking or synthesizing array elements on a microarray is accomplished using photolithography, piezo printing (see inkjet printers, Baldeschweiler et al., Supra), mechanical microspotting techniques and the like. It is possible. In each of the above techniques, the substrate should be a solid, non-porous solid (Schena (1999). Supra). Recommended substrates include silicon, silica, glass slides, glass chips and silicon wafers. Alternatively, arrays similar to dot blotting or slot blotting can be used to place and bond elements to the surface of the substrate by thermal, ultraviolet, or chemical or mechanical bonding means. Regular arrays can be made using available methods and machinery and can contain any suitable number of elements (Schena, M. et al. (1995) S
cience 270: 467-470, Shalon. D. et al. (1996) Genome Res. 6: 639-645, Marshall.
, A. and J. Hodgson (1998) Nat. Biotechnol. 16: 27-31.).

Full-length cDNA, expressed gene sequence fragment (EST), or fragments or oligomers thereof can be elements of the microarray. Fragments and oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array element is hybridized with the polynucleotide in the biological sample. The polynucleotide in the biological sample is attached to a fluorescent label or other molecular tag to facilitate detection. After hybridization, unhybridized nucleotides are removed from the biological sample and the fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may also be used to detect hybridization. The degree of complementarity and relative abundance of each polynucleotide that hybridizes to the elements on the microarray can be calculated. The preparation and use of the microarray in one embodiment is detailed below.

Preparation of Tissue or Cell Samples Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly (A) ⁺ RNA is purified using the oligo (dT) cellulose method. Each poly (A) ⁺ RNA sample contained MMLV reverse transcriptase, 0.05 pg / μl oligo (dT) primer (21mer), 1x
First strand buffer, 0.03 units / μl RNase inhibitor, 500 μM dATP, 5
Reverse transcribing with 00 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). This reverse transcription reaction was performed using the GEMBRIGHT kit (Incyte) in 25 ml containing 200 ng of poly (A) ⁺ RNA.
Do with capacity. A specific control poly (A) ⁺ RNA is synthesized from non-coding yeast genomic DNA by in vitro transcription. After incubation at 370 ° C for 2 hours, each reaction sample (one labeled with Cy3 and the other labeled with Cy5) was treated with 2.5 ml of 0.5M sodium hydroxide and incubated at 850 ° C for 20 minutes to stop the reaction. To denature the RNA. Samples are purified using two consecutive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA). After conjugation, the two reaction samples were treated with 1 ml of glycogen (1 mg / ml), 6 ml.
Ethanol precipitate with 0 ml sodium acetate and 300 ml 100% ethanol. Samples of SpeedVAC (Savant Instruments Inc., Holbrook NY
) To finish and resuspend in 14 μl 5 × SSC / 0.2% SDS.

Preparation of Microarrays Arrays of the invention are used to make array elements. Each array element is amplified from bacterial cells containing the vector containing the cloned cDNA insert.
PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified by PCR for 30 cycles from an initial amount of 1-2 ng to a final amount of more than 5 μg. The amplified array element is SEPHACRYL-40
Purify using 0 (Amersham Pharmacia Biotech).

The purified array elements are fixed on polymer-coated glass slides. Microscope glass slides (Corning) are washed with a large amount of distilled water during and after the treatment and ultrasonically washed in 0.1% SDS and acetone. 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), W
est Chester PA), washed extensively in distilled water,
Coat with 0.05% aminopropylsilane (Sigma) in% ethanol. The coated glass slide is cured by heating at 110 ° C.

Array elements are added to a coated glass substrate using the method described in US Pat. No. 5,807,522. References to this patent are incorporated herein by reference. 1 μl of the array element DNA with an average concentration of 100 ng / μl was opened using an open capillary printing element (open capillary) using a high-speed mechanical device.
Fill the printing element). The instrument then dispenses approximately 5 nl of array element sample per slide.

Microarrays are UV crosslinked using the STRATALINKER UV crosslinker (Stratagene). The microarray is washed once with 0.2% SDS at room temperature and three times with distilled water. The non-specific binding site is phosphate buffered saline (PBS) (Trop
Microarrays are incubated in 0.2% casein (IX, Inc., Bedford MA) for 30 minutes at 60 ° C., then blocked by washing with 0.2% SDS and distilled water as described above.

Hybridization The hybridization reaction solution contained 9 μl of sample mixture containing 0.2 μg of each of the Cy3 and Cy5 labeled cDNA synthesis products in 5 × SSC, 0.2% SDS hybridization buffer. . The sample mixture is heated at 65 ° C. for 5 minutes, aliquoted onto the microarray surface and covered with a 1.8 cm ² cover glass. The array is transferred to a waterproof chamber with a cavity slightly larger than the microscope slide. Add 140 μl of 5 × SSC to the corner of the chamber and adjust the humidity in the chamber to 10
Hold at 0%. The chamber containing this array is incubated at 60 ° C. for approximately 6.5 hours. Arrays were prepared in the first wash buffer (1 × SSC, 0.1% SDS) 45
Wash 3 times for 10 minutes each in the second wash buffer (0.1 x SSC) at 45 ° C for 10 minutes, then dry.

Detection Reporter Labeled Hybridization Complex can Generate Spectral Lines at 488 nm for Exciting Cy3 and 632 nm for Exciting Cy3 Inn
Detection with a microscope equipped with an ova 70 gas 10 W laser (Coherent, Inc., Santa Clara CA). A 20 × microscope objective (Nikon, Inc., Melville NY) is used to focus the excitation laser light on the array. The slide containing this array is placed on the computer-controlled XY stage of the microscope and raster scanned through the objective lens. The 1.8 cm × 1.8 cm array used in this example is scanned at a resolution of 20 μm.

In two different scans, the mixed gas multi-line laser excites two phosphors sequentially. The emitted light corresponds to two fluorophores based on wavelength, two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Brid
gewater NJ). The signal is filtered using a suitable filter placed between the array and the photomultiplier tube. The maximum emission of the phosphor used is Cy3
Is 565 nm, and Cy5 is 650 nm. The instrument can record spectra from both phosphors at the same time, but with a suitable filter for the laser source, one scan per phosphor and usually two scans of each array.

Scan sensitivity is usually calibrated using the signal intensity generated by a cDNA control species added to a known concentration of sample mixture. A specific position on the array contains a complementary DNA sequence such that the intensity of the signal at that position correlates to a weight ratio of the hybridizing species of 1: 100,000. Two samples from different samples (eg representing test cells and control cells) are each labeled with a different fluorophore and hybridized to a single array to identify genes that are differentially expressed. The calibration is carried out by labeling a sample of calibrating cDNA with two fluorophores and adding equal volumes to the hybridization mixture.

The output of the photomultiplier tube is a 12-bit RTI-835H analog-digital (AID) conversion board (Analog Device) installed in an IBM compatible PC computer.
s, Inc., Norwood MA). The digitized data has a signal intensity of blue (low signal) to red (using a linear 20-color conversion).
It is displayed as an image that is mapped into the pseudo color range up to (high signal). The data is also analyzed quantitatively. If two different fluorophores are excited at the same time for measurement, then the emission spectrum of each fluorophore is used to first correct the data for optical crosstalk between the fluorophores (due to the overlapping emission spectra). .

The grid is superimposed on the fluorescent signal image so that the signal from each spot is centered on each element of the grid. The fluorescent signals within each element are integrated and a number corresponding to the average intensity of the signal is obtained. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

9 A complementary polynucleotide to the sequence encoding the complementary polynucleotide HTFS, or any portion thereof, may be
It is used to reduce or inhibit the expression of HTFS. Although the use of oligonucleotides containing from about 15 to about 30 base pairs is described, essentially the same method can be used with smaller or larger sequence fragments. Oligo4
Appropriate oligonucleotides are designed using .06 software (National Biosciences) and the coding sequence of HTFS. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5'sequence and used to prevent the promoter from binding to the coding sequence. To inhibit translation, complementary oligonucleotides are designed to prevent the ribosome from binding to the HTFS-encoding transcript.

10 Expression of HTFS Expression and purification of HTFS can be performed using a bacterial or virus based expression system. For HTFS expression in bacteria, the cDNA is subcloned into a suitable vector containing an inducible promoter that enhances antibiotic resistance and the transcription level of the cDNA. Such promoters include, but are not limited to, the T5 or T7 bacteriophage promoter associated with the lac operator regulatory element and the trp-lac (tac) hybrid promoter. The recombinant vector is transformed into a suitable bacterial host such as BL21 (DE3). Bacteria with antibiotic resistance express HTFS when induced with isopropyl β-D thiogalactopyranoside (IPTG). Expression of HTFS in eukaryotic cells is carried out by infecting insect or mammalian cell lines with the Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with the cDNA encoding HTFS by either homologous recombination or bacterial mediated gene transfer with transfer plasmid mediated. Viral infectivity is maintained and the strong polyhedrin promoter results in high levels of cDNA transcription. Recombinant baculovirus is often used to infect Spodoptera frugiperda (Sf9) insect cells, but can also be used to infect human hepatocytes. In the case of the latter infection, further genetic modification of the baculovirus is required. (For example, Engelhard.EK et al. (1994) Proc. Natl. Acad. Sci. USA 91: 3224-3227; S
andig, V. et al. (1996) Hum. Gene Ther. 7: 1937-1945.).

In most expression systems, HTFS is used, for example glutathione S transferase (GST).
, Or a fusion protein synthesized with a peptide epitope tag such as FLAG or 6-His, the affinity-based purification of the recombinant fusion protein from crude cell lysate can be performed rapidly in one step. The 26-kilodalton enzyme GST from Schistosoma japonicum enables purification of fusion proteins with immobilized glutathione while maintaining protein activity and antigenicity (Amersham Pharma
cia Biotech). After purification, the GST moiety can be proteolytically cleaved from HTFS at specific manipulation sites. FLAG, a peptide of 8 amino acids, allows immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). A stretch of 6 consecutive histidine residues, 6-His, allows purification on a metal chelate resin (QIAGEN). Methods for protein expression and purification are described in Ausubel (1995, supra, ch 10, 16). HTFS purified by these methods can be used directly to perform the assays of Examples 11 and 15 below.

Demonstration of 11 HTFS Activity Galactosyltransferase activity is determined by measuring the transfer of galactose from UDP galactose to GlcNAc-terminated oligosaccharides in a radioactivity assay (Kolbinger. , F et al. (1998) J.
Biol. Chem. 273: 58-65). Samples of HTSF were 14 μl assay stock solution (180 mM sodium cacodylate, pH 6.5, 1 mg / ml bovine serum albumin, 0.2
6 mM UDP-galactose, 2 μl UDP- [ ³ H] galactose), 1 μl MnCl ₂ (
500 mM), and of _{2.5 μl GlcNAcβO- (CH 2) -} 8 CO 2 Me (37 mg / ml in dimethyl sulfate),
Incubate for 60 minutes at 37 ° C. The reaction was stopped by the addition of 1 ml water and loaded onto a C18 Sep-Pak cartridge (Waters) and the column was washed twice with 5 ml water to remove unreacted UDP- [ ³ H] galactose. To be washed. [ ³ H]
Galactosylation _{GlcNAcβO- (CH 2) - 8 CO} 2 Me remains bound to the column during the washing with water, eluted with 5 ml of methanol. Radioactivity in eluted methanol is measured by liquid scintillation counter. This radioactivity is proportional to the activity of galactosyltransferase in the starting sample.

In an alternative example, the activity of methyltransferase is determined by a method that measures the transfer of radiolabeled methyl groups from a donor substrate to an acceptor substrate (Bokar, J.
A. et al.). The reaction mixture (final volume 50 μl) is 15 mM HEPES, pH 7.9, 1.5 m
M MgCI ₂ , 10 mM dithiothreitol, 3% polyvinyl alcohol, 1.5 μCi [
Methyl- ³ H] AdoMet (0.375 μM AdoMet) (DuPont-NEN), 0.6 μg HTFS, and acceptor substrate (0.4 μg [ ³⁵ S] RNA or 6-mercaptopurine (6-MP), final concentration 1 mM) Including. The reaction mixture is incubated at 30 ° C for 30 minutes and then at 65 ° C for 5 minutes.

[0266] [methyl - ³ H] Analysis of RNA is performed as follows. 1) 50 μl of 2 x buffer (20
mM tris-HCl, pH 7.6, 1 M LiCl, 1 mM EDTA, 1% sodium dodecyl sulfate (
SDS)) and 50 μl oligo d (T) -cellulose (10 mg / ml in 1 × buffer) are added to the reaction mixture and incubated for 30 minutes at room temperature with stirring. 2)
The reaction mixture is transferred to a 96-well plate attached to a vacuum device. 3) Each sample was washed with 2.4 ml of three 2.4 ml aliquots of 1 x oligo d (T) buffer containing 0.5% SDS, 0.1% SDS or no SDS at all. To be done. 4) RNA was thawed in a 96-well plate with 300 μl of water and transferred to scintillation vials containing liquid scintillant,
There the radioactivity is measured.

Analysis of [methyl- ³ H] 6-MP is performed as follows. 1) Add 500 μl of 0 to the reaction mixture
.5 M borate buffer (pH 10.0) is added, followed by 2.5 ml of 20% (v / v) isoamyl alcohol in toluene. 2) The sample is vortexed vigorously for 10 seconds to mix. 3) After centrifugation at 700 g for 10 minutes, 15 ml of the organic phase is transferred to a scintillation vial containing 0.5 ml absolute ethanol and liquid scintillation and the radioactivity is determined. 4) The results obtained are corrected for the 6-MP organic phase extracted in the organic phase (approximately 41%).

12 Functional Assay HTFS function is at physiologically elevated levels in mammalian cell culture systems.
Evaluation is by expression of the sequence encoding HTFS. The cDNA is subcloned into a mammalian expression vector containing a strong promoter that expresses the cDNA at high levels.
Such vectors include pCMV SPORT ^™ (Life Technologies.) And pCR 3.1 (In
Vitrogen, Carlsbad, CA), both containing the cytomegalovirus promoter. For example, 5 to 10 μg of the recombinant vector is transiently transfected into a human cell line derived from endothelium or hematopoiesis by liposome preparation or electroporation. In addition, 1-2 μg of plasmid containing the sequence encoding the labeled protein is co-transfected. Expression of the labeled protein allows to distinguish between transfected and non-transfected cells. In addition, by expressing the labeled protein, the cDNA
The expression from the recombinant vector can be accurately predicted. Such labeled proteins include green fluorescent protein (GFP; Clontech), and CD64 or CD64-GFP fusion protein. Automatic flow cytometry using a technology based on laser optics (F
CM) is used to identify transfected cells expressing GFP or CD64-GFP and to assess their apoptotic status and other cellular characteristics. In addition, FCM detects and weighs uptake of fluorescent molecules that diagnoses the phenomenon of preceding or simultaneous cell death. These phenomena include nuclear DNA measured by staining DNA with propidium iodide.
Changes in contents, down-regulation of DNA synthesis as measured by reduced uptake of bromodeoxyuridine, and changes in protein expression on cell surface and intracellular as measured by reactivity with specific antibodies. , Changes in plasma membrane composition measured by binding of fluorescent-complexed annexin V protein to the cell surface. Flow cytometry is by Ormerod, MG (1994) Flow Cytometry Oxford, New York,
It is listed in NY.

The effect of HTFS on gene expression is dependent on the sequence encoding HTFS and CD64 or CD64-G.
Highly purified cell populations transfected with either FP can be evaluated. CD64 or CD64-GFP is expressed on the surface of transformed cells and binds to a conserved region of human immunoglobulin G (IgG). Transformed and non-transformed cells can be separated using magnetic beads coated with either human IgG or antibodies against CD64 (DYNAL. Lake Success. NY). mRNA can be purified from cells by methods well known in the art. The expression of mRNA encoding HTFS and other genes of interest can be analyzed by Northern analysis or microarray technology.

13 Production of Antibodies Specific for HTFS Polyacrylamide gel electrophoresis (PAGE; eg, Harrington, MG (1990)
Methods Enzymol. 1816-3088-495) or other purification techniques and HTFS substantially purified using standard protocols to immunize rabbits to generate antibodies.

Alternatively, the HTFS amino acid sequence can be analyzed using LASERGENE software (DNASTAR) to determine highly immunogenic regions and the corresponding oligopeptides synthesized and used to determine well known methods to those of skill in the art. To produce antibodies. Selection of suitable epitopes, such as those near the C-terminus or within adjacent hydrophilic regions, is well known in the art (see, eg, Ausubel, 1995, supra, Chapter 11).

Oligopeptides, typically about 15 residues in length, were labeled with ABI 431A from Applied Biosystems.
Synthesized by chemistry of fmoc method using a peptide synthesizer (PE Biosystems), and N-maleimidobenzoyl-N-hydroxysuccinimide ester (
MBS) to bind to KLH (Sigma-Aldrich, St. Louis MO),
Enhances immunogenicity (see, eg, Ausubel, 1995, supra). Rabbits are immunized with the oligopeptide-KLH complex in Freund's complete adjuvant.
To test the anti-peptide activity and anti-HTFS activity of the obtained antiserum, the peptide or HTFS was bound to a substrate, blocked with 1% BSA, reacted with rabbit antiserum and washed, and then radioactive React with goat anti-rabbit IgG labeled with iodine.

Purification of native HTFS using 14 specific antibodies Native HTFS or recombinant HTFS is substantially purified by immunoaffinity chromatography using antibodies specific for HTFS. The immunoaffinity column is formed by covalently linking an anti-HTFS antibody with a resin for activation chromatography such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After binding, the resin is blocked and washed according to the manufacturer's instructions.

A culture solution containing HTFS is passed through an immunoaffinity column, and the column is washed under conditions capable of preferentially adsorbing HTFS (for example, with a buffer having high ionic strength in the presence of a surfactant). The column is eluted under conditions that break the binding between the antibody and HTFS (for example, with a buffer of pH 2-3 or a high concentration of chaotropic ion such as urea or thiocyanate ion), and HTFS is recovered.

Identification of Molecules that Interact with 15 HTFS HTFS, or a biologically active fragment thereof, was identified as ¹²⁵ I Bolton Hunter Reagent (see, eg, Bolton AE and WM Hunter (1973) Biochem. J. 133: 529). Label with. Pre-arranged candidate molecules in a multi-well plate are labeled with HTFS
Incubate with, wash and assay all wells with labeled HTFS complex. The data obtained at various HTFS concentrations are used to calculate values for the number and affinity, association of HTFS bound to the candidate molecule.

Alternatively, a molecule that interacts with HTFS can be prepared using the method of Fields, S. and O. Song (1989, Nature
340: 245-246). Yeast two-hybrid syst
em) and MATCHMAKER system (Clontech) for analysis using a commercially available kit based on a 2-hybrid system.

HTFS also uses a high-throughput yeast two-hybrid system for PA
The THCALLING process (CuraGen Corp., New Haven CT) can be used to determine all interactions between proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) US Patent No. No. 6,057,101).

Those skilled in the art will be able to make various modifications of the described methods and systems of the present invention without departing from the scope and spirit of the invention. Although the present invention has been described with reference to particular preferred embodiments, it should be understood that the scope of the invention should not be unduly limited to such particular embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

BRIEF DESCRIPTION OF THE TABLES Table 1 lists the polypeptide and nucleotide sequences used to generate HTFS-encoding full length sequences (SEQ ID NO), clone identification number, cDNA.
A library and a cDNA fragment are shown.

Table 2 lists the characteristics of each polypeptide sequence, including latent motifs and homologous sequences, and
The method, algorithm, and searchable database used for HTFS analysis are shown.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence determined by Northern analysis, the diseases, disorders and conditions associated with these tissues and the vectors in which each DNA was cloned.

Table 4 shows the tissues used to create the cDNA library in which the cDNA clone encoding HTFS was isolated.

Table 5 lists the tools used to analyze the polynucleotides and polypeptides of the invention,
The programs and algorithms, their description, references, and threshold parameters are shown.

[Table 1]

[Table 2]

[Table 3]

[Table 4]

[Table 5]

[Table 6]

[Table 7]

[Table 8]

[Table 9]

[Table 10]

[Table 11]

[Table 12]

[Table 13]

[Table 14]

[Table 15]

[Table 16]

[Table 17]

[Table 18]

[Table 19]

[Table 20]

[Table 21]

[Table 22]

[Table 23]

[Table 24]

[Table 25]

[Table 26]

[Table 27]

[Table 28]

[Table 29]

[Sequence list]

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) A61P 1/04 A61P 3/10 4C084 1/16 7/00 4H045 3/10 7/06 7/00 9 / 10 101 7/06 11/00 9/10 101 11/06 11/00 13/12 11/06 17/00 13/12 17/06 17/00 19/02 17/06 19/10 19/02 25 / 00 19/10 29/00 25/00 31/18 29/00 35/00 31/18 35/02 35/00 37/06 35/02 37/08 37/06 C07K 16/40 37/08 C12N 1 / 15 C07K 16/40 1/19 C12N 1/15 1/21 1/19 9/10 1/21 C12Q 1/48 Z 5/10 1/68 A 9/10 G01N 33/15 Z C12Q 1/48 33 / 50 Z 1/68 33/53 MG 01N 33/15 33/566 33/50 C12N 15/00 ZNAA 33/53 5/00 A 33/566 A61K 37/52 (81) Designated country EP (AT, BE, CH) , CY, DE, DK, ES, FI, FR, GB, GR, IE, IT , LU, MC, NL, PT, SE, TR), OA (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG), AP (GH , GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), EA (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB , GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, S , SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW (72) Inventor Hillman, Jennifer El, California 94040, USA -Mountain View # 17-Monro Road Live 230 (72) Inventor Lal, Pretty 95054 California, United States Santa Clara Russ Drive 2382 (72) Inventor Bandman, Olga 94043 California, United States-Mountain View Anna Avenue 366 ( 72) Inventor Patterson, Chandra United States California 94025 Menlo Park # 1 Sherwood Way 490 (72) Inventor Sea Leo El United States California 94303 Palo Alto Apartment Be Tan Land Drive 1081 (72) Inventor Azimza , Yarda USA California 94552 · Castro Valley Boulder Canyon Drive 5518 (72) Inventor Ryu, Dung Aina Em United States California 95123 · San Jose Coy Drive 233 (72) Inventor Bogun, Mariah Earl United States California 94577 San Leandro Santiago Road 14244 F Term (reference) 2G045 AA34 AA35 CB01 DA13 DA36 FA12 FA29 FB02 FB08 FB12 GC15 4B024 AA01 AA11 BA10 CA04 CA09 FA02 HA01 HA14 4B050 CC03 DD11 LL01 LL03 4B063Q25QR QR QA19 Q43 QRAQ CA29 CA44 CA46 4C084 AA02 AA03 AA06 AA07 AA13 AA17 BA01 BA02 BA20 BA21 BA22 CA53 DC25 NA14 ZA022 ZA452 ZA512 ZA592 ZA752 ZA812 ZA892 ZA942 ZA972 ZB112 ZB132 ZB262 ZB272 ZC352 ZC11 4H045 A50

Claims (28)

[Claims] 1. An isolated polypeptide comprising: (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 42 (SEQ ID NO: 1-42); b) a natural amino acid sequence having at least 90% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42, and (c) selected from the group consisting of SEQ ID NO: 1-42. A biologically active fragment of an amino acid sequence, and (d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-42, (a)-(d). An isolated polypeptide comprising an amino acid sequence selected from the group: 2. The isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO: 1-42. 3. An isolated polynucleotide encoding the polypeptide of claim 1. 4. An isolated polynucleotide encoding the polypeptide of claim 2. 5. The isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO: 43-84. 6. A recombinant polynucleotide comprising a promoter sequence operably linked to the polynucleotide of claim 3. 7. A cell transformed with the recombinant polynucleotide of claim 6. 8. A genetically modified organism containing the recombinant polynucleotide according to claim 6. 9. A method for producing the polypeptide of claim 1, which is (a) operably linked to a polynucleotide encoding the polypeptide of claim 1 under conditions suitable for expression of said polypeptide. The polypeptide of claim 1, comprising the steps of culturing cells transformed with a recombinant polynucleotide containing the expressed promoter sequence, and (b) recovering the polypeptide so expressed. Production method. 10. An isolated antibody that specifically binds to the polypeptide of claim 1. 11. An isolated polynucleotide comprising: (a) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-84; and (b) a group consisting of SEQ ID NO: 43-84. A natural polynucleotide sequence having at least 90% sequence identity with a polynucleotide sequence selected from (c) a polynucleotide sequence complementary to (a) above, and (d) a polynucleotide sequence complementary to (b) above. Isolated polynucleotide sequence, and (e) a polynucleotide sequence selected from the group consisting of the RNA equivalents of (a) to (d) above. 12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of the polynucleotide of claim 11. 13. A method for detecting a target polynucleotide having the polynucleotide sequence according to claim 11 in a sample, comprising: (a) at least 20 comprising a sequence complementary to the target polynucleotide in the sample. Hybridizing the sample with a probe comprising a number of contiguous nucleotides, wherein the probe binds to the target polynucleotide under conditions where a hybridization complex of the probe with the target polynucleotide or fragment thereof is formed. Specifically hybridizing to a nucleotide, and (b) detecting the presence or absence of the hybridization complex and optionally measuring the yield if present. A method for detecting a target polynucleotide. 14. The method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides. 15. A method of detecting a target polynucleotide having the polynucleotide sequence of claim 11 in a sample, the method comprising: (a) amplifying the target polynucleotide or a fragment thereof using polymerase chain reaction amplification. And (b) detecting whether or not the amplified target polynucleotide or a fragment thereof is present, and if present, optionally measuring the yield thereof, the target polynucleotide. Detection method. 16. A composition comprising an effective amount of the polypeptide of claim 1 and a pharmaceutically acceptable excipient. 17. The polypeptide according to claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-42.
Composition. 18. A method for treating a disease associated with reduced expression of functional HTFS or a symptom thereof, which comprises administering the composition of claim 16 to a patient in need of such treatment. And treatment method. 19. A method of screening a compound effective as an agonist of the polypeptide of claim 1, comprising the step of: (a) exposing a sample containing the polypeptide of claim 1 to the compound; Detecting the agonist activity of the sample. 20. A composition comprising an agonist compound identified by the screening method of claim 19 and a pharmaceutically acceptable excipient. 21. A method of treating a disease associated with reduced expression of functional HTFS or a symptom thereof, comprising administering the composition of claim 20 to a patient in need of such treatment. And treatment method. 22. A method of screening a compound effective as an antagonist of the polypeptide of claim 1, comprising: (a) exposing a sample containing the polypeptide of claim 1 to the compound; Detecting antagonist activity in the sample. 23. A composition comprising an antagonist compound identified by the screening method of claim 22 and a pharmaceutically acceptable excipient. 24. A method of treating a disease associated with overexpression of functional HTFS or a symptom thereof, comprising administering the composition of claim 23 to a patient in need of such treatment. And treatment method. 25. A method for screening a compound that specifically binds to the polypeptide of claim 1, comprising the step of: (a) binding the polypeptide of claim 1 to at least one test compound under suitable conditions. And (b) the step of detecting the binding between the polypeptide of claim 1 and the test compound to identify the compound that specifically binds to the polypeptide of claim 1. . 26. A method of screening a compound that modulates the activity of the polypeptide of claim 1, comprising: (a) at least one test compound of the polypeptide of claim 1 under conditions permitting its activity. And (b) evaluating the activity of the polypeptide of claim 1 in the presence of the test compound, and (c) the activity of the polypeptide of claim 1 in the presence of the test compound. And comparing the activity of the polypeptide of claim 1 in the absence of the test compound with the change in activity of the polypeptide of claim 1 in the presence of the test compound. A method for screening, which indicates the presence of a compound that regulates the activity of the polypeptide of 27. A method of screening a compound effective for altering the expression of a target polynucleotide comprising the sequence of claim 5, comprising: (a) under conditions suitable for expression of the target polynucleotide, Exposing a sample containing the target polynucleotide to a compound, (b) detecting a change in expression of the target polynucleotide, and (c) the target polynucleotide in the presence of varying amounts of the compound. And a step of comparing the expression of the target polynucleotide in the absence of the compound. 28. A method for assessing the toxicity of a test compound, the method comprising: (a) treating a biological sample containing a nucleic acid with the test compound; and (b) treating the nucleic acid of the biological sample. Hybridizing under a condition that a specific hybridization complex is formed between the probe containing at least 20 contiguous nucleotides of said polynucleotide and the target polynucleotide of said biological sample. And wherein the target polynucleotide comprises the polynucleotide sequence of the polynucleotide of claim 11 or a fragment thereof, (c) measuring the yield of hybridization complexes, and (d) in the treated biological sample. The yield of hybridization complex was determined by Comparing the yield of the hybridization complex in the pull, and the difference in the yield of the hybridization complex in the treated biological sample is indicative of the toxicity of the test compound. .